≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Early syphilis, including avohilmo

Endpoint Browser PheWeb

AB1_EARLY_SYPHILIS_WIDE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Primary healthcare outpatient: ICD-10 — A51
  • Hospital discharge: ICD-10 — A51
  • Hospital discharge: ICD-9 — 09[1]
  • Hospital discharge: ICD-8 — 09[1]
  • Cause of death: ICD-10 — A51
  • Cause of death: ICD-9 — 09[1]
  • Cause of death: ICD-8 — 09[1]

3 out of 7 registries used, show all original rules.

527

4. Check minimum number of events

None

527

5. Include endpoints

None

527

6. Filter based on genotype QC (FinnGen only)

482

Control definitions (FinnGen only)

Control exclude
AB1_SEXUAL_TRANSMISSION

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF13

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 482 156 326
Unadjusted period prevalence (%) 0.12 0.06 0.15
Median age at first event (years) 38.18 30.03 42.08

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
527
Matched controls
5270
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Z11.3
ICD-10 Finland
Special screening examination for infections with a predominantly sexual mode of transmission
22.9
269.8
239
184
B23.1
ICD-10 Finland
HIV disease resulting in (persistent) generalized lymphadenopathy
134.9
230.2
116
11
A51.3
ICD-10 Finland
Secondary syphilis of skin and mucous membranes
+∞
224.5
199
*
A51.0
ICD-10 Finland
Primary genital syphilis
+∞
209.8
187
*
WW200
NOMESCO Finland
Immunization
27.4
157.3
113
52
A56.0
ICD-10 Finland
Chlamydial infection of lower genitourinary tract
45.0
153.5
93
25
A63.0
ICD-10 Finland
Anogenital (venereal) warts
38.7
147.3
93
29
A56.3
ICD-10 Finland
Chlamydial infection of anus and rectum
1432.5
120.8
113
*
A54.6
ICD-10 Finland
Gonococcal infection of anus and rectum
+∞
101.4
94
*
A51.9
ICD-10 Finland
Early syphilis, unspecified
+∞
89.1
83
*
Y25
ICPC
Fear sexually transm disease male
10.2
89.0
112
136
A54.5
ICD-10 Finland
Gonococcal pharyngitis
966.5
86.1
82
*
A54.0
ICD-10 Finland
Gonococcal infection of lower genitourinary tract without periurethral or accessory gland abscess
+∞
70.4
66
*
Z29.2
ICD-10 Finland
Other prophylactic chemotherapy
132.6
56.1
59
5
Z21
ICD-10 Finland
Asymptomatic human immunodeficiency virus [HIV] infection status
200.1
53.0
54
*
A53.9
ICD-10 Finland
Syphilis, unspecified
+∞
51.9
49
*
B24
ICD-10 Finland
Unspecified human immunodeficiency virus [HIV] disease
76.5
49.1
55
8
D06BB04
ATC
podophyllotoxin; topical
6.8
48.7
83
140
A60.0
ICD-10 Finland
Herpesviral infection of genitalia and urogenital tract
16.3
43.8
38
25
09100
ICD-8 Finland
Early syphilis, symptomatic, Primary syphilis, except extragenital chancre
+∞
43.3
41
*
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
4.5
32.0
89
230
A51.5
ICD-10 Finland
Early syphilis, latent
+∞
26.3
25
*
Z20.2
ICD-10 Finland
Contact with and exposure to infections with a predominantly sexual mode of transmission
6.6
25.3
42
68
Y70
ICPC
Syphilis male
+∞
25.2
24
*
A56.4
ICD-10 Finland
Chlamydial infection of pharynx
136.5
24.8
26
*
Z3231
NOMESCO Finland
Registered nurse
2.7
24.4
177
822
0913A
ICD-9 Finland
Early syphilis, symptomatic, Secondary syphilis of skin or mucous membranes
+∞
24.1
23
*
R87.6
ICD-10 Finland
Abnormal findings in specimens from female genital organs, abnormal cytological findings
4.9
23.2
54
120
Y71
ICPC
Gonorrhoea male
+∞
23.1
22
*
Z2221
NOMESCO Finland
Medical doctor
2.7
22.9
168
781
09120
ICD-8 Finland
Early syphilis, symptomatic, Secondary syphilis of skin and mucous membranes
+∞
21.0
20
*
ULA02
NOMESCO Finland
Kolposcopy
4.4
20.9
55
135
Z25.1
ICD-10 Finland
Need for immunization against influenza
4.6
19.9
49
114
B23.8
ICD-10 Finland
HIV disease resulting in other specified conditions
109.2
19.7
21
*
A51.4
ICD-10 Finland
Other secondary syphilis
+∞
17.8
17
*
B23.0
ICD-10 Finland
Acute HIV infection syndrome
+∞
16.8
16
*
J05AB11
ATC
valaciclovir; oral
2.7
15.7
101
432
A55
ICD-10 Finland
Chlamydial lymphogranuloma (venereum)
+∞
15.7
15
*
J01MA02
ATC
ciprofloxacin; systemic
2.1
15.4
211
1252
ZX114
NOMESCO Finland
Intramuscular
11.8
15.4
28
25
LDC03
NOMESCO Finland
Conisation of cervix uteri using diathermy or laser
6.9
15.4
24
36
EB1AA, ,
SPAT
3.6
15.4
53
158
D06BB10
ATC
imiquimod; topical
4.3
15.0
40
99
LDA20
NOMESCO Finland
Biopsy of vaginal cervix
4.5
14.5
36
84
D11
ICPC
Diarrhoea
2.6
14.1
94
408
Y99
ICPC
Genital disease male other
20.7
13.9
20
10
J05AB01
ATC
aciclovir; systemic
2.3
13.1
122
615
TAB00
NOMESCO Finland
Lumbar puncture
3.7
13.1
42
119
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
2.1
12.5
167
969
LFB00
NOMESCO Finland
Biopsy of vulva or perineum
12.0
12.4
22
19
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.2
12.2
127
668
WX110, ,
SPAT
3.3
11.7
45
144
A52.1
ICD-10 Finland
Symptomatic neurosyphilis
+∞
11.5
11
*
A52.9
ICD-10 Finland
Late syphilis, unspecified
+∞
11.5
11
*
WNF00
NOMESCO Finland
Infection source and contact determination
35.9
11.3
14
*
Z71.8
ICD-10 Finland
Other specified counselling
1.9
11.3
199
1263
Z76.0
ICD-10 Finland
Issue of repeat prescription
2.0
10.8
163
978
WX290, ,
SPAT
4.0
10.8
31
81
J01AA02
ATC
doxycycline; systemic
2.0
10.8
390
3102
EB1SA, ,
SPAT
3.3
10.5
41
132
A54.9
ICD-10 Finland
Gonococcal infection, unspecified
+∞
10.4
10
*
J01DB01
ATC
cefalexin; oral
2.2
9.7
445
3763
J01FA10
ATC
azithromycin; systemic
1.8
9.6
316
2396
A97
ICPC
No disease
2.0
9.5
115
637
A56.2
ICD-10 Finland
Chlamydial infection of genitourinary tract, unspecified
30.6
9.4
12
*
Z20.6
ICD-10 Finland
Contact with and exposure to human immunodeficiency virus [HIV]
22.2
9.4
13
6
I84
ICD-10 Finland
Hemorrhoids
4.7
9.1
21
46
D06AX01
ATC
fusidic acid; topical
2.4
9.0
64
285
N48.1
ICD-10 Finland
Balanoposthitis
3.4
8.9
33
103
LEB00
NOMESCO Finland
Biopsy of vagina
8.7
8.4
17
20
0910A
ICD-9 Finland
Early syphilis, symptomatic, Genital syphilis (primary)
+∞
8.4
8
*
A53.0
ICD-10 Finland
Latent syphilis, unspecified as early or late
+∞
8.4
8
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
1.9
8.3
114
656
U07
ICPC
Urine symptom/complaint other
2.8
8.3
43
164
N05BA04
ATC
oxazepam; oral
1.9
8.2
132
800
N06AX11
ATC
mirtazapine; oral
1.7
8.1
183
1229
P01AB01
ATC
metronidazole; oral, rectal
1.7
7.9
187
1270
S29
ICPC
Skin symptom/complaint other
1.9
7.7
103
586
F43.29
ICD-10 Finland
Adaptation disorder UNS
3.9
7.6
22
58
Z03
ICD-10 Finland
Medical observation and evaluation for suspected diseases and conditions, ruled out
2.5
7.4
49
211
K03.65
ICD-10 Finland
Deposits [accretions] on teeth betel
1.8
7.4
125
768
A03.3
ICD-10 Finland
Shigellosis due to Shigella sonnei
+∞
7.3
7
*
A51.1
ICD-10 Finland
Primary anal syphilis
+∞
7.3
7
*
A03.1
ICD-10 Finland
Shigellosis due to Shigella flexneri
+∞
7.3
7
*
B17.1
ICD-10 Finland
Acute hepatitis C
20.3
7.2
10
5
R74
ICPC
Upper respiratory infection acute
1.7
7.0
196
1384
Z01.7
ICD-10 Finland
Laboratory examination
1.9
6.7
94
542
R4120
NOMESCO Finland
Occupational therapy
2.6
6.6
37
147
F41.2
ICD-10 Finland
Mixed anxiety and depressive disorder
2.0
6.6
71
375
D01BA02
ATC
terbinafine; oral
1.7
6.4
136
889
N48.8
ICD-10 Finland
Other specified disorders of penis
8.3
6.4
13
16
N05CF01
ATC
zopiclone; oral
1.7
6.3
144
958
A52.8
ICD-10 Finland
Late syphilis, latent
+∞
6.3
6
*
A51.2
ICD-10 Finland
Primary syphilis of other sites
+∞
6.3
6
*
A52.3
ICD-10 Finland
Neurosyphilis, unspecified
+∞
6.3
6
*
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
2.3
6.2
46
209
EMB10
NOMESCO Finland
Tonsillectomy
2.4
6.1
40
171
B18.2
ICD-10 Finland
Chronic viral hepatitis C
4.2
6.1
16
39
K62.5
ICD-10 Finland
Haemorrhage of anus and rectum
2.8
6.1
31
117
B37.4
ICD-10 Finland
Candidiasis of other urogenital sites
12.7
6.1
10
8
D19
ICPC
Teeth/gum symptom/complaint
1.6
6.1
170
1191
F52.2
ICD-10 Finland
Failure of genital response
3.1
6.0
25
84

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
2.1e+00
2.6e+00
4.7e+00
—
5.0e+00
3.8e+00
2.7e+00
cases:31.14%
controls:5.04%
cases:21.49%
controls:1.91%
cases:24.56%
controls:0.29%
—
—
cases:31.87%
controls:0.31%
cases:44.87%
controls:1.81%
cases:45.10%
controls:5.33%
142
229
314
4318
98
87
358
4460
112
13
344
4534
—
145
14
310
4531
201
81
247
4402
184
217
224
3856
Infectious Disease
44 [38004484]
2.9e+00
3.8e+00
—
1.0e+50
4.9e+00
4.1e+00
3.2e+00
cases:19.96%
controls:1.32%
cases:18.64%
controls:0.53%
—
—
cases:7.68%
controls:0.00%
cases:12.75%
controls:0.11%
cases:24.55%
controls:0.56%
cases:28.43%
controls:1.64%
91
60
365
4487
85
24
371
4523
—
35
0
421
4547
58
5
397
4540
110
25
338
4458
116
67
292
4006
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
2.0e+00
2.9e+00
4.4e+00
1.0e+50
2.7e+00
3.1e+00
2.9e+00
cases:17.11%
controls:2.60%
cases:12.50%
controls:0.79%
cases:9.65%
controls:0.13%
cases:1.75%
controls:0.00%
cases:1.98%
controls:0.13%
cases:15.85%
controls:0.83%
cases:30.15%
controls:2.41%
78
118
378
4429
57
36
399
4511
44
6
412
4541
8
0
448
4547
9
6
446
4539
71
37
377
4446
123
98
285
3975
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
1.5e+00
2.2e+00
4.4e+00
—
3.1e+00
2.6e+00
1.7e+00
cases:17.11%
controls:4.53%
cases:14.47%
controls:1.78%
cases:17.32%
controls:0.26%
—
—
cases:3.96%
controls:0.18%
cases:18.30%
controls:1.56%
cases:20.59%
controls:4.69%
78
206
378
4341
66
81
390
4466
79
12
377
4535
—
18
8
437
4537
82
70
366
4413
84
191
324
3882
Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
6357-8 [3024950]
2.1e+00
2.9e+00
4.9e+00
—
—
3.1e+00
2.3e+00
cases:20.83%
controls:3.23%
cases:19.08%
controls:1.30%
cases:19.52%
controls:0.18%
—
—
—
—
cases:20.54%
controls:1.20%
cases:29.17%
controls:3.90%
95
147
361
4400
87
59
369
4488
89
8
367
4539
—
—
92
54
356
4429
119
159
289
3914
Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
21416-3 [3003510]
2.0e+00
2.8e+00
4.8e+00
—
—
3.1e+00
2.4e+00
cases:18.86%
controls:3.08%
cases:17.32%
controls:1.30%
cases:16.01%
controls:0.15%
—
—
—
—
cases:18.97%
controls:1.09%
cases:28.43%
controls:3.46%
86
140
370
4407
79
59
377
4488
73
7
383
4540
—
—
85
49
363
4434
116
141
292
3932
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
2.0e+00
2.6e+00
3.4e+00
—
—
3.0e+00
2.8e+00
cases:10.53%
controls:1.63%
cases:5.92%
controls:0.48%
cases:4.61%
controls:0.15%
—
—
—
—
cases:8.71%
controls:0.47%
cases:19.12%
controls:1.35%
48
74
408
4473
27
22
429
4525
21
7
435
4540
—
—
39
21
409
4462
78
55
330
4018
Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection
24111-7 [3011371]
2.8e+00
3.5e+00
—
—
—
3.9e+00
3.0e+00
cases:15.79%
controls:1.14%
cases:15.35%
controls:0.57%
—
—
—
—
—
—
cases:18.75%
controls:0.45%
cases:24.75%
controls:1.62%
72
52
384
4495
70
26
386
4521
—
—
—
84
20
364
4463
101
66
307
4007
Venereal disease screening
171128005 [4064905]
3.6e+00
4.8e+00
1.0e+50
1.0e+50
1.0e+50
—
4.5e+00
cases:18.86%
controls:0.66%
cases:11.84%
controls:0.11%
cases:15.13%
controls:0.00%
cases:1.10%
controls:0.00%
cases:1.76%
controls:0.00%
—
—
cases:30.64%
controls:0.47%
86
30
370
4517
54
5
402
4542
69
0
387
4547
5
0
451
4547
8
0
447
4545
—
125
19
283
4054
Protein [Mass/volume] in Urine
2888-6 [3037121]
3.8e+00
—
1.0e+50
—
—
4.5e+00
4.5e+00
cases:9.87%
controls:0.24%
—
—
cases:3.07%
controls:0.00%
—
—
—
—
cases:10.49%
controls:0.13%
cases:19.12%
controls:0.27%
45
11
411
4536
—
14
0
442
4547
—
—
47
6
401
4477
78
11
330
4062
Emergency Room Visit
ER [9203]
6.8e-01
9.1e-01
2.7e+00
5.0e+00
1.4e+00
1.0e+00
8.8e-01
cases:41.89%
controls:26.81%
cases:20.61%
controls:9.48%
cases:15.57%
controls:1.23%
cases:14.25%
controls:0.11%
cases:3.96%
controls:0.97%
cases:20.31%
controls:8.25%
cases:44.36%
controls:24.80%
191
1219
265
3328
94
431
362
4116
71
56
385
4491
65
5
391
4542
18
44
437
4501
91
370
357
4113
181
1010
227
3063
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
1.8e+00
2.7e+00
—
—
2.5e+00
3.2e+00
2.4e+00
cases:8.77%
controls:1.50%
cases:9.43%
controls:0.70%
—
—
—
—
cases:1.54%
controls:0.13%
cases:12.50%
controls:0.60%
cases:18.38%
controls:1.99%
40
68
416
4479
43
32
413
4515
—
—
7
6
448
4539
56
27
392
4456
75
81
333
3992
Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
21613-5 [3006093]
2.6e+00
3.3e+00
—
—
—
3.8e+00
2.8e+00
cases:16.89%
controls:1.54%
cases:15.79%
controls:0.68%
—
—
—
—
—
—
cases:19.20%
controls:0.54%
cases:25.25%
controls:1.96%
77
70
379
4477
72
31
384
4516
—
—
—
86
24
362
4459
103
80
305
3993
Fear sexually transm disease male
Y25 [2002001393]
2.6e+00
3.3e+00
—
—
—
3.2e+00
2.6e+00
cases:7.89%
controls:0.64%
cases:3.95%
controls:0.15%
—
—
—
—
—
—
cases:3.57%
controls:0.16%
cases:7.60%
controls:0.59%
36
29
420
4518
18
7
438
4540
—
—
—
16
7
432
4476
31
24
377
4049
Outpatient Visit
OP [9202]
4.9e-01
6.4e-01
1.1e+00
4.9e+00
2.1e+00
1.4e+00
8.9e-01
cases:69.08%
controls:57.75%
cases:52.19%
controls:36.64%
cases:19.96%
controls:7.35%
cases:38.38%
controls:0.46%
cases:39.34%
controls:7.35%
cases:66.96%
controls:34.04%
cases:81.37%
controls:64.30%
315
2626
141
1921
238
1666
218
2881
91
334
365
4213
175
21
281
4526
179
334
276
4211
300
1526
148
2957
332
2619
76
1454
Kolposcopy
ULA02 [2001306679]
2.1e+00
3.2e+00
—
1.0e+50
—
3.1e+00
2.5e+00
cases:2.85%
controls:0.37%
cases:2.63%
controls:0.11%
—
—
cases:3.95%
controls:0.00%
—
—
cases:2.90%
controls:0.13%
cases:4.90%
controls:0.42%
13
17
443
4530
12
5
444
4542
—
18
0
438
4547
—
13
6
435
4477
20
17
388
4056
Treatment of a patient needing special arrangements
WYA30 [2001310874]
2.0e+00
3.1e+00
—
—
—
3.1e+00
2.4e+00
cases:5.48%
controls:0.77%
cases:3.29%
controls:0.15%
—
—
—
—
—
—
cases:4.91%
controls:0.22%
cases:9.31%
controls:0.88%
25
35
431
4512
15
7
441
4540
—
—
—
22
10
426
4473
38
36
370
4037
Medical doctor
Z2221 [2001311556]
8.7e-01
1.3e+00
2.3e+00
1.0e+50
2.2e+00
2.0e+00
1.7e+00
cases:7.46%
controls:3.25%
cases:3.73%
controls:1.06%
cases:1.75%
controls:0.18%
cases:1.75%
controls:0.00%
cases:1.32%
controls:0.15%
cases:5.80%
controls:0.80%
cases:9.80%
controls:2.01%
34
148
422
4399
17
48
439
4499
8
8
448
4539
8
0
448
4547
6
7
449
4538
26
36
422
4447
40
82
368
3991
Treponema pallidum Ab [Presence] in Serum
22587-0 [3019832]
2.3e+00
3.1e+00
—
1.0e+50
—
2.6e+00
2.1e+00
cases:16.23%
controls:1.96%
cases:15.13%
controls:0.84%
—
—
cases:5.48%
controls:0.00%
—
—
cases:8.71%
controls:0.67%
cases:16.67%
controls:2.43%
74
89
382
4458
69
38
387
4509
—
25
0
431
4547
—
39
30
409
4453
68
99
340
3974
sildenafil; oral
G04BE03 [21602648]
1.2e+00
1.6e+00
2.2e+00
—
1.8e+00
1.5e+00
1.5e+00
cases:8.33%
controls:2.73%
cases:8.99%
controls:2.05%
cases:3.51%
controls:0.40%
—
—
cases:3.08%
controls:0.53%
cases:10.27%
controls:2.61%
cases:19.36%
controls:5.13%
38
124
418
4423
41
93
415
4454
16
18
440
4529
—
14
24
441
4521
46
117
402
4366
79
209
329
3864
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
8.3e-01
1.6e+00
2.1e+00
—
1.6e+00
1.9e+00
1.3e+00
cases:10.53%
controls:4.88%
cases:10.53%
controls:2.38%
cases:4.39%
controls:0.55%
—
—
cases:1.76%
controls:0.35%
cases:14.29%
controls:2.36%
cases:22.30%
controls:7.56%
48
222
408
4325
48
108
408
4439
20
25
436
4522
—
8
16
447
4529
64
106
384
4377
91
308
317
3765
Differential panel, method unspecified - Blood
69738-3 [42870588]
8.5e-01
1.4e+00
2.2e+00
—
1.6e+00
1.6e+00
1.6e+00
cases:8.55%
controls:3.85%
cases:9.21%
controls:2.44%
cases:4.39%
controls:0.53%
—
—
cases:2.42%
controls:0.51%
cases:12.05%
controls:2.65%
cases:21.81%
controls:5.57%
39
175
417
4372
42
111
414
4436
20
24
436
4523
—
11
23
444
4522
54
119
394
4364
89
227
319
3846
Short blood count panel - Blood
55429-5 [40758558]
1.3e+00
1.4e+00
1.4e+00
—
1.6e+00
1.8e+00
1.5e+00
cases:11.62%
controls:3.30%
cases:7.46%
controls:2.02%
cases:2.63%
controls:0.66%
—
—
cases:2.20%
controls:0.44%
cases:10.04%
controls:1.87%
cases:17.65%
controls:4.42%
53
150
403
4397
34
92
422
4455
12
30
444
4517
—
10
20
445
4525
45
84
403
4399
72
180
336
3893
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
9.1e-01
1.3e+00
2.3e+00
—
1.7e+00
1.4e+00
1.3e+00
cases:12.06%
controls:5.26%
cases:9.21%
controls:2.66%
cases:4.17%
controls:0.44%
—
—
cases:2.64%
controls:0.51%
cases:11.61%
controls:3.23%
cases:24.75%
controls:8.03%
55
239
401
4308
42
121
414
4426
19
20
437
4527
—
12
23
443
4522
52
145
396
4338
101
327
307
3746
Basophils/Leukocytes in Blood
30180-4 [3022096]
9.1e-01
1.3e+00
2.0e+00
—
1.5e+00
1.5e+00
1.3e+00
cases:13.82%
controls:6.05%
cases:12.72%
controls:3.83%
cases:6.14%
controls:0.84%
—
—
cases:3.30%
controls:0.75%
cases:16.52%
controls:4.04%
cases:25.98%
controls:8.67%
63
275
393
4272
58
174
398
4373
28
38
428
4509
—
15
34
440
4511
74
181
374
4302
106
353
302
3720
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
9.3e-01
1.3e+00
2.0e+00
—
1.5e+00
1.5e+00
1.3e+00
cases:14.04%
controls:6.05%
cases:12.72%
controls:3.85%
cases:5.92%
controls:0.84%
—
—
cases:3.30%
controls:0.75%
cases:16.52%
controls:4.06%
cases:25.98%
controls:8.69%
64
275
392
4272
58
175
398
4372
27
38
429
4509
—
15
34
440
4511
74
182
374
4301
106
354
302
3719
Monocytes/Leukocytes in Blood
26485-3 [3019069]
9.2e-01
1.3e+00
2.0e+00
—
1.5e+00
1.5e+00
1.3e+00
cases:14.04%
controls:6.14%
cases:12.72%
controls:3.85%
cases:5.92%
controls:0.84%
—
—
cases:3.30%
controls:0.77%
cases:16.52%
controls:4.06%
cases:25.98%
controls:8.69%
64
279
392
4268
58
175
398
4372
27
38
429
4509
—
15
35
440
4510
74
182
374
4301
106
354
302
3719
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
9.6e-01
1.3e+00
2.0e+00
—
1.4e+00
1.5e+00
1.3e+00
cases:14.69%
controls:6.18%
cases:12.94%
controls:3.72%
cases:6.14%
controls:0.86%
—
—
cases:3.08%
controls:0.81%
cases:16.52%
controls:4.08%
cases:25.98%
controls:9.13%
67
281
389
4266
59
169
397
4378
28
39
428
4508
—
14
37
441
4508
74
183
374
4300
106
372
302
3701
Treponema pallidum Ab [Titer] in Serum by Hemagglutination
26009-1 [3019539]
3.2e+00
—
1.0e+50
1.0e+50
1.0e+50
—
5.2e+00
cases:8.55%
controls:0.37%
—
—
cases:23.25%
controls:0.00%
cases:6.14%
controls:0.00%
cases:3.30%
controls:0.00%
—
—
cases:24.26%
controls:0.17%
39
17
417
4530
—
106
0
350
4547
28
0
428
4547
15
0
440
4545
—
99
7
309
4066
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
9.2e-01
1.3e+00
2.0e+00
—
1.4e+00
1.5e+00
1.3e+00
cases:14.69%
controls:6.40%
cases:12.72%
controls:3.96%
cases:6.14%
controls:0.86%
—
—
cases:3.30%
controls:0.81%
cases:16.52%
controls:4.10%
cases:26.47%
controls:9.18%
67
291
389
4256
58
180
398
4367
28
39
428
4508
—
15
37
440
4508
74
184
374
4299
108
374
300
3699
CD3+CD4+ (T4 helper) cells/cells in Blood
8123-2 [3014037]
3.8e+00
—
—
—
—
—
4.6e+00
cases:4.82%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
cases:10.78%
controls:0.12%
22
5
434
4542
—
—
—
—
—
44
5
364
4068
Reagin Ab [Titer] in Serum by VDRL
50690-7 [3029634]
3.2e+00
—
1.0e+50
1.0e+50
1.0e+50
—
5.1e+00
cases:8.77%
controls:0.37%
—
—
cases:25.44%
controls:0.00%
cases:7.46%
controls:0.00%
cases:7.47%
controls:0.00%
—
—
cases:32.35%
controls:0.29%
40
17
416
4530
—
116
0
340
4547
34
0
422
4547
34
0
421
4545
—
132
12
276
4061
Laboratory Visit
OMOP4822461 [32036]
1.2e-01
4.7e-01
1.9e+00
4.2e+00
1.0e+00
6.5e-01
1.7e-01
cases:30.92%
controls:28.35%
cases:34.65%
controls:24.90%
cases:32.68%
controls:6.66%
cases:15.57%
controls:0.26%
cases:18.02%
controls:7.41%
cases:40.85%
controls:26.52%
cases:52.45%
controls:48.20%
141
1289
315
3258
158
1132
298
3415
149
303
307
4244
71
12
385
4535
82
337
373
4208
183
1189
265
3294
214
1963
194
2110
Monocytes [#/volume] in Blood
26484-6 [3001604]
8.8e-01
1.2e+00
2.1e+00
—
1.5e+00
1.4e+00
1.2e+00
cases:14.04%
controls:6.36%
cases:12.50%
controls:4.05%
cases:6.36%
controls:0.86%
—
—
cases:3.52%
controls:0.84%
cases:16.52%
controls:4.53%
cases:26.23%
controls:9.85%
64
289
392
4258
57
184
399
4363
29
39
427
4508
—
16
38
439
4507
74
203
374
4280
107
401
301
3672
Basophils [#/volume] in Blood
26444-0 [3006315]
8.8e-01
1.2e+00
2.0e+00
—
1.5e+00
1.4e+00
1.2e+00
cases:14.04%
controls:6.33%
cases:12.50%
controls:4.05%
cases:6.14%
controls:0.86%
—
—
cases:3.52%
controls:0.84%
cases:16.52%
controls:4.51%
cases:26.23%
controls:9.85%
64
288
392
4259
57
184
399
4363
28
39
428
4508
—
16
38
439
4507
74
202
374
4281
107
401
301
3672
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
8.9e-01
1.2e+00
2.1e+00
—
1.4e+00
1.4e+00
1.2e+00
cases:14.69%
controls:6.58%
cases:12.72%
controls:4.16%
cases:6.36%
controls:0.86%
—
—
cases:3.52%
controls:0.86%
cases:16.52%
controls:4.62%
cases:26.72%
controls:10.21%
67
299
389
4248
58
189
398
4358
29
39
427
4508
—
16
39
439
4506
74
207
374
4276
109
416
299
3657
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
6.2e-01
1.1e+00
2.1e+00
—
2.2e+00
1.6e+00
1.2e+00
cases:2.85%
controls:1.56%
cases:3.29%
controls:1.08%
cases:1.54%
controls:0.20%
—
—
cases:1.32%
controls:0.15%
cases:5.80%
controls:1.23%
cases:12.25%
controls:4.08%
13
71
443
4476
15
49
441
4498
7
9
449
4538
—
6
7
449
4538
26
55
422
4428
50
166
358
3907
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
8.2e-01
1.1e+00
2.1e+00
—
1.6e+00
1.3e+00
1.1e+00
cases:16.01%
controls:7.74%
cases:10.96%
controls:4.09%
cases:5.04%
controls:0.62%
—
—
cases:1.76%
controls:0.35%
cases:12.95%
controls:3.86%
cases:30.15%
controls:12.45%
73
352
383
4195
50
186
406
4361
23
28
433
4519
—
8
16
447
4529
58
173
390
4310
123
507
285
3566
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
9.4e-01
1.3e+00
3.1e+00
—
—
1.5e+00
1.1e+00
cases:6.80%
controls:2.77%
cases:3.95%
controls:1.06%
cases:3.95%
controls:0.18%
—
—
—
—
cases:4.46%
controls:1.05%
cases:8.58%
controls:3.07%
31
126
425
4421
18
48
438
4499
18
8
438
4539
—
—
20
47
428
4436
35
125
373
3948
Eosinophils [#/volume] in Blood
26449-9 [3013115]
8.5e-01
1.2e+00
2.0e+00
—
1.4e+00
1.4e+00
1.1e+00
cases:14.47%
controls:6.73%
cases:12.72%
controls:4.16%
cases:6.36%
controls:0.90%
—
—
cases:3.52%
controls:0.92%
cases:16.52%
controls:4.66%
cases:26.47%
controls:10.31%
66
306
390
4241
58
189
398
4358
29
41
427
4506
—
16
42
439
4503
74
209
374
4274
108
420
300
3653
podophyllotoxin
D06BB04 [21602086]
1.9e+00
—
—
1.0e+50
—
3.4e+00
2.6e+00
cases:3.95%
controls:0.64%
—
—
—
—
cases:4.17%
controls:0.00%
—
—
cases:4.02%
controls:0.13%
cases:3.43%
controls:0.27%
18
29
438
4518
—
—
19
0
437
4547
—
18
6
430
4477
14
11
394
4062
Need for immunization against influenza
Z25.1 [45581017]
2.1e+00
2.3e+00
—
—
—
1.8e+00
1.6e+00
cases:2.85%
controls:0.35%
cases:1.54%
controls:0.15%
—
—
—
—
—
—
cases:1.79%
controls:0.31%
cases:2.45%
controls:0.52%
13
16
443
4531
7
7
449
4540
—
—
—
8
14
440
4469
10
21
398
4052
Abnormal findings in specimens from female genital organs, abnormal cytological findings
R87.6 [45558487]
2.3e+00
3.5e+00
—
—
—
2.3e+00
1.7e+00
cases:3.29%
controls:0.33%
cases:3.51%
controls:0.11%
—
—
—
—
—
—
cases:1.12%
controls:0.11%
cases:2.45%
controls:0.47%
15
15
441
4532
16
5
440
4542
—
—
—
5
5
443
4478
10
19
398
4054
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
8.9e-01
1.2e+00
1.8e+00
—
1.1e+00
1.4e+00
1.1e+00
cases:16.01%
controls:7.24%
cases:14.04%
controls:4.86%
cases:6.80%
controls:1.23%
—
—
cases:3.96%
controls:1.30%
cases:16.96%
controls:4.97%
cases:27.45%
controls:10.97%
73
329
383
4218
64
221
392
4326
31
56
425
4491
—
18
59
437
4486
76
223
372
4260
112
447
296
3626
Normoblasts [#/volume] in Blood
715-3 [3021589]
8.7e-01
1.1e+00
1.7e+00
—
1.1e+00
1.3e+00
1.1e+00
cases:11.84%
controls:5.32%
cases:11.84%
controls:4.42%
cases:5.48%
controls:1.10%
—
—
cases:3.30%
controls:1.10%
cases:16.07%
controls:4.89%
cases:24.02%
controls:9.50%
54
242
402
4305
54
201
402
4346
25
50
431
4497
—
15
50
440
4495
72
219
376
4264
98
387
310
3686
valaciclovir; oral
J05AB11 [21603137]
1.1e+00
1.1e+00
2.2e+00
—
2.0e+00
4.2e-01
1.4e+00
cases:3.07%
controls:1.08%
cases:1.54%
controls:0.51%
cases:1.54%
controls:0.18%
—
—
cases:1.32%
controls:0.18%
cases:1.12%
controls:0.74%
cases:6.13%
controls:1.57%
14
49
442
4498
7
23
449
4524
7
8
449
4539
—
6
8
449
4537
5
33
443
4450
25
64
383
4009
Leukocytes [#/volume] in Urine
30405-5 [3018095]
8.4e-01
1.1e+00
2.0e+00
—
1.7e+00
1.4e+00
1.3e+00
cases:7.24%
controls:3.25%
cases:4.82%
controls:1.63%
cases:2.19%
controls:0.31%
—
—
cases:1.32%
controls:0.24%
cases:6.92%
controls:1.72%
cases:17.65%
controls:5.72%
33
148
423
4399
22
74
434
4473
10
14
446
4533
—
6
11
449
4534
31
77
417
4406
72
233
336
3840
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
5.1e-01
1.2e+00
2.9e+00
—
—
1.5e+00
1.1e+00
cases:3.95%
controls:2.40%
cases:3.51%
controls:1.10%
cases:1.97%
controls:0.11%
—
—
—
—
cases:6.03%
controls:1.47%
cases:13.24%
controls:4.86%
18
109
438
4438
16
50
440
4497
9
5
447
4542
—
—
27
66
421
4417
54
198
354
3875
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.7e-01
7.5e-01
1.5e+00
2.5e+00
7.2e-01
7.3e-01
4.0e-01
cases:25.44%
controls:20.74%
cases:26.32%
controls:14.45%
cases:10.96%
controls:2.73%
cases:1.32%
controls:0.11%
cases:6.15%
controls:3.08%
cases:28.57%
controls:16.15%
cases:44.61%
controls:34.96%
116
943
340
3604
120
657
336
3890
50
124
406
4423
6
5
450
4542
28
140
427
4405
128
724
320
3759
182
1424
226
2649
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
2.0e+00
1.0e+00
—
—
—
2.2e+00
2.2e+00
cases:6.36%
controls:0.95%
cases:1.54%
controls:0.57%
—
—
—
—
—
—
cases:4.24%
controls:0.47%
cases:9.80%
controls:1.15%
29
43
427
4504
7
26
449
4521
—
—
—
19
21
429
4462
40
47
368
4026
Biopsy of vaginal cervix
LDA20 [2001306656]
1.9e+00
—
—
1.0e+50
—
2.5e+00
2.1e+00
cases:1.54%
controls:0.24%
—
—
—
—
cases:1.97%
controls:0.00%
—
—
cases:1.34%
controls:0.11%
cases:2.45%
controls:0.32%
7
11
449
4536
—
—
9
0
447
4547
—
6
5
442
4478
10
13
398
4060
aciclovir; oral, parenteral
J05AB01 [21603131]
9.1e-01
1.4e+00
2.7e+00
—
-1.0e+50
9.0e-01
1.2e+00
cases:4.17%
controls:1.72%
cases:2.63%
controls:0.68%
cases:1.97%
controls:0.13%
—
—
cases:0.00%
controls:0.18%
cases:1.79%
controls:0.74%
cases:7.35%
controls:2.38%
19
78
437
4469
12
31
444
4516
9
6
447
4541
—
0
8
455
4537
8
33
440
4450
30
97
378
3976
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.6e-01
8.6e-01
1.5e+00
—
1.4e+00
9.4e-01
9.5e-01
cases:16.45%
controls:10.09%
cases:12.72%
controls:5.81%
cases:5.48%
controls:1.30%
—
—
cases:3.96%
controls:1.06%
cases:15.18%
controls:6.56%
cases:31.37%
controls:15.07%
75
459
381
4088
58
264
398
4283
25
59
431
4488
—
18
48
437
4497
68
294
380
4189
128
614
280
3459
Case Management Agency
251B00000X [38004193]
-1.4e-02
2.4e-01
9.9e-01
4.3e+00
5.5e-01
3.3e-01
1.7e-01
cases:48.25%
controls:48.60%
cases:48.46%
controls:42.51%
cases:33.55%
controls:15.81%
cases:39.04%
controls:0.84%
cases:24.40%
controls:15.64%
cases:54.02%
controls:45.80%
cases:70.83%
controls:67.20%
220
2210
236
2337
221
1933
235
2614
153
719
303
3828
178
38
278
4509
111
711
344
3834
242
2053
206
2430
289
2737
119
1336
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
7.1e-01
1.0e+00
1.7e+00
—
—
9.9e-01
1.3e+00
cases:7.68%
controls:3.94%
cases:5.48%
controls:2.00%
cases:2.41%
controls:0.46%
—
—
—
—
cases:5.58%
controls:2.14%
cases:19.12%
controls:6.02%
35
179
421
4368
25
91
431
4456
11
21
445
4526
—
—
25
96
423
4387
78
245
330
3828
Hepatitis B virus surface Ab [Units/volume] in Serum
16935-9 [3023421]
1.5e+00
1.6e+00
—
—
—
2.3e+00
1.7e+00
cases:2.19%
controls:0.48%
cases:1.54%
controls:0.31%
—
—
—
—
—
—
cases:1.34%
controls:0.13%
cases:3.68%
controls:0.69%
10
22
446
4525
7
14
449
4533
—
—
—
6
6
442
4477
15
28
393
4045
Supplier / Service Provider
OMOP5117446 [33004]
-8.9e-01
-1.3e+00
3.8e-01
—
—
3.3e+00
4.3e+00
cases:12.72%
controls:26.26%
cases:2.63%
controls:8.67%
cases:1.54%
controls:1.06%
—
—
—
—
cases:3.57%
controls:0.13%
cases:16.67%
controls:0.27%
58
1194
398
3353
12
394
444
4153
7
48
449
4499
—
—
16
6
432
4477
68
11
340
4062
Lumbar puncture
TAB00 [2001300538]
—
—
—
—
—
3.1e+00
2.2e+00
—
—
—
—
—
—
—
—
—
—
cases:2.46%
controls:0.11%
cases:2.21%
controls:0.25%
—
—
—
—
—
11
5
437
4478
9
10
399
4063
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
4.5e-01
1.0e+00
1.4e+00
—
9.1e-01
8.4e-01
6.5e-01
cases:20.39%
controls:14.05%
cases:22.37%
controls:9.52%
cases:7.89%
controls:1.98%
—
—
cases:5.27%
controls:2.20%
cases:21.65%
controls:10.66%
cases:37.01%
controls:23.42%
93
639
363
3908
102
433
354
4114
36
90
420
4457
—
24
100
431
4445
97
478
351
4005
151
954
257
3119
Hepatitis A virus IgG Ab [Presence] in Serum by Immunoassay
40724-7 [3040363]
2.5e+00
1.0e+50
—
—
—
—
2.7e+00
cases:1.32%
controls:0.11%
cases:1.10%
controls:0.00%
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.20%
6
5
450
4542
5
0
451
4547
—
—
—
—
12
8
396
4065
Hepatitis B virus core and surface Ab and surface Ag panel - Serum
77190-7 [46237023]
1.4e+00
—
—
—
—
2.1e+00
1.6e+00
cases:2.41%
controls:0.62%
—
—
—
—
—
—
—
—
cases:1.56%
controls:0.20%
cases:3.19%
controls:0.64%
11
28
445
4519
—
—
—
—
7
9
441
4474
13
26
395
4047
azithromycin; oral, parenteral
J01FA10 [21602978]
7.7e-01
1.0e+00
2.3e+00
—
—
7.2e-01
8.7e-01
cases:17.54%
controls:8.95%
cases:7.02%
controls:2.60%
cases:2.19%
controls:0.22%
—
—
—
—
cases:4.91%
controls:2.45%
cases:15.69%
controls:7.24%
80
407
376
4140
32
118
424
4429
10
10
446
4537
—
—
22
110
426
4373
64
295
344
3778
pH of Urine
2756-5 [3015736]
4.1e-01
9.4e-01
2.0e+00
—
1.5e+00
1.1e+00
8.7e-01
cases:6.14%
controls:4.18%
cases:4.61%
controls:1.85%
cases:2.19%
controls:0.31%
—
—
cases:1.32%
controls:0.31%
cases:6.92%
controls:2.36%
cases:16.42%
controls:7.59%
28
190
428
4357
21
84
435
4463
10
14
446
4533
—
6
14
449
4531
31
106
417
4377
67
309
341
3764
Diarrhoea
D11 [2002000310]
1.5e+00
1.4e+00
—
—
—
1.8e+00
1.4e+00
cases:4.82%
controls:1.08%
cases:1.32%
controls:0.33%
—
—
—
—
—
—
cases:1.79%
controls:0.29%
cases:6.13%
controls:1.64%
22
49
434
4498
6
15
450
4532
—
—
—
8
13
440
4470
25
67
383
4006
Hepatitis A virus IgM Ab [Presence] in Serum
22314-9 [3013327]
1.4e+00
—
—
—
—
2.3e+00
2.1e+00
cases:1.32%
controls:0.33%
—
—
—
—
—
—
—
—
cases:1.34%
controls:0.13%
cases:3.43%
controls:0.44%
6
15
450
4532
—
—
—
—
6
6
442
4477
14
18
394
4055
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
3.3e-01
5.7e-01
1.5e+00
2.3e+00
7.0e-01
3.9e-01
3.3e-01
cases:23.25%
controls:17.84%
cases:17.11%
controls:10.49%
cases:8.33%
controls:2.07%
cases:1.32%
controls:0.13%
cases:4.40%
controls:2.22%
cases:16.52%
controls:11.78%
cases:35.54%
controls:28.38%
106
811
350
3736
78
477
378
4070
38
94
418
4453
6
6
450
4541
20
101
435
4444
74
528
374
3955
145
1156
263
2917
Pharmacy visit
OMOP4822462 [581458]
5.0e-01
5.8e-01
8.2e-01
2.1e+00
3.4e-01
7.3e-01
7.8e-01
cases:91.45%
controls:86.63%
cases:80.92%
controls:70.40%
cases:48.90%
controls:29.60%
cases:10.75%
controls:1.41%
cases:37.36%
controls:29.90%
cases:84.15%
controls:71.89%
cases:96.08%
controls:91.82%
417
3939
39
608
369
3201
87
1346
223
1346
233
3201
49
64
407
4483
170
1359
285
3186
377
3223
71
1260
392
3740
16
333
Platelets [#/volume] in Blood
26515-7 [3007461]
1.9e-01
5.9e-01
1.1e+00
2.0e+00
5.8e-01
4.7e-01
2.3e-01
cases:26.75%
controls:23.20%
cases:27.85%
controls:17.68%
cases:11.40%
controls:4.09%
cases:1.32%
controls:0.18%
cases:7.03%
controls:4.07%
cases:27.90%
controls:19.52%
cases:46.32%
controls:40.68%
122
1055
334
3492
127
804
329
3743
52
186
404
4361
6
8
450
4539
32
185
423
4360
125
875
323
3608
189
1657
219
2416
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.8e-01
5.8e-01
1.1e+00
2.0e+00
5.8e-01
4.8e-01
2.3e-01
cases:26.75%
controls:23.33%
cases:27.85%
controls:17.77%
cases:11.40%
controls:4.16%
cases:1.32%
controls:0.18%
cases:7.03%
controls:4.07%
cases:28.35%
controls:19.61%
cases:46.57%
controls:40.88%
122
1061
334
3486
127
808
329
3739
52
189
404
4358
6
8
450
4539
32
185
423
4360
127
879
321
3604
190
1665
218
2408
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.8e-01
5.9e-01
1.1e+00
2.0e+00
5.8e-01
4.7e-01
2.3e-01
cases:26.75%
controls:23.31%
cases:28.07%
controls:17.81%
cases:11.40%
controls:4.13%
cases:1.32%
controls:0.18%
cases:7.03%
controls:4.07%
cases:28.13%
controls:19.65%
cases:46.57%
controls:40.93%
122
1060
334
3487
128
810
328
3737
52
188
404
4359
6
8
450
4539
32
185
423
4360
126
881
322
3602
190
1667
218
2406
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.8e-01
5.8e-01
1.1e+00
2.0e+00
5.8e-01
4.7e-01
2.3e-01
cases:26.75%
controls:23.31%
cases:27.85%
controls:17.77%
cases:11.40%
controls:4.13%
cases:1.32%
controls:0.18%
cases:7.03%
controls:4.07%
cases:28.13%
controls:19.61%
cases:46.57%
controls:40.85%
122
1060
334
3487
127
808
329
3739
52
188
404
4359
6
8
450
4539
32
185
423
4360
126
879
322
3604
190
1664
218
2409
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.8e-01
5.8e-01
1.1e+00
2.0e+00
5.8e-01
4.7e-01
2.3e-01
cases:26.75%
controls:23.33%
cases:27.85%
controls:17.79%
cases:11.40%
controls:4.13%
cases:1.32%
controls:0.18%
cases:7.03%
controls:4.07%
cases:28.13%
controls:19.61%
cases:46.57%
controls:40.83%
122
1061
334
3486
127
809
329
3738
52
188
404
4359
6
8
450
4539
32
185
423
4360
126
879
322
3604
190
1663
218
2410
MCH [Entitic mass]
28539-5 [3035941]
1.8e-01
5.7e-01
1.1e+00
2.0e+00
5.8e-01
4.8e-01
2.3e-01
cases:26.75%
controls:23.33%
cases:27.63%
controls:17.73%
cases:11.40%
controls:4.13%
cases:1.32%
controls:0.18%
cases:7.03%
controls:4.07%
cases:28.13%
controls:19.56%
cases:46.57%
controls:40.83%
122
1061
334
3486
126
806
330
3741
52
188
404
4359
6
8
450
4539
32
185
423
4360
126
877
322
3606
190
1663
218
2410
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.9e-01
5.8e-01
1.1e+00
2.0e+00
5.7e-01
4.7e-01
2.3e-01
cases:26.97%
controls:23.40%
cases:27.85%
controls:17.79%
cases:11.40%
controls:4.16%
cases:1.32%
controls:0.18%
cases:7.03%
controls:4.09%
cases:28.13%
controls:19.63%
cases:46.57%
controls:40.88%
123
1064
333
3483
127
809
329
3738
52
189
404
4358
6
8
450
4539
32
186
423
4359
126
880
322
3603
190
1665
218
2408
Internal Medicine
11 [38004456]
1.7e-01
-4.6e-02
1.1e+00
2.6e+00
1.1e+00
3.3e-01
4.7e-01
cases:17.98%
controls:15.59%
cases:6.36%
controls:6.64%
cases:2.85%
controls:0.95%
cases:1.97%
controls:0.15%
cases:2.42%
controls:0.84%
cases:8.48%
controls:6.22%
cases:21.32%
controls:14.53%
82
709
374
3838
29
302
427
4245
13
43
443
4504
9
7
447
4540
11
38
444
4507
38
279
410
4204
87
592
321
3481
Dermatitis, unspecified
L30.9 [45572271]
6.7e-01
1.3e+00
2.6e+00
—
—
1.1e+00
1.3e-01
cases:2.41%
controls:1.25%
cases:2.41%
controls:0.66%
cases:1.75%
controls:0.13%
—
—
—
—
cases:2.23%
controls:0.76%
cases:2.45%
controls:2.16%
11
57
445
4490
11
30
445
4517
8
6
448
4541
—
—
10
34
438
4449
10
88
398
3985
Sytologyspecimen from mouth of uterus
XLD00 [2001306651]
1.2e+00
—
—
—
—
2.3e+00
1.6e+00
cases:1.54%
controls:0.46%
—
—
—
—
—
—
—
—
cases:1.56%
controls:0.16%
cases:3.43%
controls:0.71%
7
21
449
4526
—
—
—
—
7
7
441
4476
14
29
394
4044
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
3.7e-01
5.2e-01
—
—
2.5e+00
7.1e-01
1.4e+00
cases:3.95%
controls:2.75%
cases:2.63%
controls:1.58%
—
—
—
—
cases:1.32%
controls:0.11%
cases:2.46%
controls:1.23%
cases:10.29%
controls:2.82%
18
125
438
4422
12
72
444
4475
—
—
6
5
449
4540
11
55
437
4428
42
115
366
3958
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
5.0e-01
8.2e-01
1.2e+00
—
5.9e-01
7.9e-01
4.8e-01
cases:21.49%
controls:14.25%
cases:20.61%
controls:10.25%
cases:8.33%
controls:2.57%
—
—
cases:5.05%
controls:2.86%
cases:22.32%
controls:11.49%
cases:36.03%
controls:25.85%
98
648
358
3899
94
466
362
4081
38
117
418
4430
—
23
130
432
4415
100
515
348
3968
147
1053
261
3020
cefalexin; oral
J01DB01 [21602870]
5.3e-01
7.1e-01
1.9e+00
—
3.8e-01
3.5e-01
6.4e-01
cases:35.75%
controls:24.70%
cases:15.13%
controls:8.03%
cases:5.26%
controls:0.79%
—
—
cases:1.32%
controls:0.90%
cases:10.71%
controls:7.78%
cases:39.22%
controls:25.41%
163
1123
293
3424
69
365
387
4182
24
36
432
4511
—
6
41
449
4504
48
349
400
4134
160
1035
248
3038
CD3+CD4+ (T4 helper) cells [#/volume] in Blood
24467-3 [3028167]
3.7e+00
—
—
—
—
—
—
cases:4.39%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
—
—
20
5
436
4542
—
—
—
—
—
—
Shigella sp [Presence] in Stool by Culture
82300-5 [42529406]
1.7e+00
—
—
—
—
—
1.9e+00
cases:2.19%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:2.45%
controls:0.39%
10
19
446
4528
—
—
—
—
—
10
16
398
4057
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
2.4e-01
5.7e-01
1.9e+00
—
1.5e+00
8.8e-01
6.3e-01
cases:6.14%
controls:4.88%
cases:4.61%
controls:2.66%
cases:2.63%
controls:0.40%
—
—
cases:1.32%
controls:0.31%
cases:6.70%
controls:2.88%
cases:16.18%
controls:9.33%
28
222
428
4325
21
121
435
4426
12
18
444
4529
—
6
14
449
4531
30
129
418
4354
66
380
342
3693
Anogenital (venereal) warts
A63.0 [45585929]
—
1.0e+50
—
—
1.0e+50
—
3.4e+00
—
—
cases:2.19%
controls:0.00%
—
—
—
—
cases:1.10%
controls:0.00%
—
—
cases:6.62%
controls:0.25%
—
10
0
446
4547
—
—
5
0
450
4545
—
27
10
381
4063
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
2.5e-01
5.5e-01
1.9e+00
—
1.4e+00
8.5e-01
6.3e-01
cases:6.36%
controls:5.04%
cases:4.61%
controls:2.71%
cases:2.63%
controls:0.42%
—
—
cases:1.32%
controls:0.33%
cases:6.70%
controls:2.99%
cases:16.67%
controls:9.60%
29
229
427
4318
21
123
435
4424
12
19
444
4528
—
6
15
449
4530
30
134
418
4349
68
391
340
3682
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2.4e-01
5.6e-01
1.9e+00
—
1.4e+00
8.6e-01
6.1e-01
cases:6.14%
controls:4.90%
cases:4.61%
controls:2.68%
cases:2.63%
controls:0.42%
—
—
cases:1.32%
controls:0.33%
cases:6.70%
controls:2.94%
cases:16.18%
controls:9.45%
28
223
428
4324
21
122
435
4425
12
19
444
4528
—
6
15
449
4530
30
132
418
4351
66
385
342
3688
Telehealth
OMOP5556618 [722455]
5.1e-01
3.9e-01
1.6e+00
—
6.0e-01
7.0e-01
4.8e-01
cases:21.71%
controls:14.27%
cases:8.11%
controls:5.63%
cases:4.61%
controls:0.92%
—
—
cases:1.76%
controls:0.97%
cases:11.61%
controls:6.11%
cases:24.51%
controls:16.72%
99
649
357
3898
37
256
419
4291
21
42
435
4505
—
8
44
447
4501
52
274
396
4209
100
681
308
3392
Gynaecological examination (general)(routine)
Z01.4 [45542395]
8.4e-01
—
—
—
—
1.9e+00
1.5e+00
cases:1.97%
controls:0.86%
—
—
—
—
—
—
—
—
cases:2.23%
controls:0.36%
cases:4.17%
controls:0.98%
9
39
447
4508
—
—
—
—
10
16
438
4467
17
40
391
4033
combinations of corticosteroids
D07AB30 [21602118]
3.6e-01
4.4e-01
1.6e+00
—
9.2e-01
1.0e+00
6.9e-01
cases:11.84%
controls:8.58%
cases:4.61%
controls:3.01%
cases:2.63%
controls:0.53%
—
—
cases:1.10%
controls:0.44%
cases:6.92%
controls:2.63%
cases:16.91%
controls:9.31%
54
390
402
4157
21
137
435
4410
12
24
444
4523
—
5
20
450
4525
31
118
417
4365
69
379
339
3694
combinations of corticosteroids
D07XB30 [21602188]
3.6e-01
4.4e-01
1.6e+00
—
9.2e-01
1.0e+00
6.9e-01
cases:11.84%
controls:8.58%
cases:4.61%
controls:3.01%
cases:2.63%
controls:0.53%
—
—
cases:1.10%
controls:0.44%
cases:6.92%
controls:2.63%
cases:16.91%
controls:9.31%
54
390
402
4157
21
137
435
4410
12
24
444
4523
—
5
20
450
4525
31
118
417
4365
69
379
339
3694
Abdominal pain/cramps general
D01 [2002000300]
1.5e+00
1.9e+00
—
—
—
—
5.6e-01
cases:2.41%
controls:0.57%
cases:1.54%
controls:0.24%
—
—
—
—
—
—
—
—
cases:2.21%
controls:1.28%
11
26
445
4521
7
11
449
4536
—
—
—
—
9
52
399
4021
hydrocortisone
D07AA02 [21602102]
4.9e-01
7.6e-01
2.3e+00
—
-1.0e+50
9.3e-01
2.5e-01
cases:8.77%
controls:5.56%
cases:3.29%
controls:1.56%
cases:1.54%
controls:0.15%
—
—
cases:0.00%
controls:0.22%
cases:4.46%
controls:1.81%
cases:7.60%
controls:6.04%
40
253
416
4294
15
71
441
4476
7
7
449
4540
—
0
10
455
4535
20
81
428
4402
31
246
377
3827
hydrocortisone
C05AA01 [21601608]
4.6e-01
8.3e-01
2.3e+00
—
-1.0e+50
9.3e-01
2.4e-01
cases:8.77%
controls:5.74%
cases:3.51%
controls:1.56%
cases:1.54%
controls:0.15%
—
—
cases:0.00%
controls:0.22%
cases:4.46%
controls:1.81%
cases:7.60%
controls:6.06%
40
261
416
4286
16
71
440
4476
7
7
449
4540
—
0
10
455
4535
20
81
428
4402
31
247
377
3826
hydrocortisone
A07EA02 [21600654]
4.6e-01
8.3e-01
2.3e+00
—
-1.0e+50
9.3e-01
2.4e-01
cases:8.77%
controls:5.74%
cases:3.51%
controls:1.56%
cases:1.54%
controls:0.15%
—
—
cases:0.00%
controls:0.22%
cases:4.46%
controls:1.81%
cases:7.60%
controls:6.06%
40
261
416
4286
16
71
440
4476
7
7
449
4540
—
0
10
455
4535
20
81
428
4402
31
247
377
3826
hydrocortisone butyrate
D07AB02 [21602106]
4.9e-01
7.6e-01
2.3e+00
—
-1.0e+50
9.3e-01
2.5e-01
cases:8.77%
controls:5.56%
cases:3.29%
controls:1.56%
cases:1.54%
controls:0.15%
—
—
cases:0.00%
controls:0.22%
cases:4.46%
controls:1.81%
cases:7.60%
controls:6.04%
40
253
416
4294
15
71
441
4476
7
7
449
4540
—
0
10
455
4535
20
81
428
4402
31
246
377
3827
hydrocortisone aceponate
D07AC16 [21602135]
4.9e-01
7.6e-01
2.3e+00
—
-1.0e+50
9.3e-01
2.5e-01
cases:8.77%
controls:5.56%
cases:3.29%
controls:1.56%
cases:1.54%
controls:0.15%
—
—
cases:0.00%
controls:0.22%
cases:4.46%
controls:1.81%
cases:7.60%
controls:6.04%
40
253
416
4294
15
71
441
4476
7
7
449
4540
—
0
10
455
4535
20
81
428
4402
31
246
377
3827
hydrocortisone buteprate
D07AB11 [21602115]
4.9e-01
7.6e-01
2.3e+00
—
-1.0e+50
9.3e-01
2.5e-01
cases:8.77%
controls:5.56%
cases:3.29%
controls:1.56%
cases:1.54%
controls:0.15%
—
—
cases:0.00%
controls:0.22%
cases:4.46%
controls:1.81%
cases:7.60%
controls:6.04%
40
253
416
4294
15
71
441
4476
7
7
449
4540
—
0
10
455
4535
20
81
428
4402
31
246
377
3827
Obstetrics / Gynecology
16 [38004461]
3.6e-01
9.1e-01
1.3e+00
—
9.3e-01
1.0e+00
4.2e-01
cases:12.50%
controls:9.08%
cases:9.65%
controls:4.13%
cases:3.07%
controls:0.86%
—
—
cases:2.20%
controls:0.88%
cases:10.04%
controls:3.93%
cases:14.71%
controls:10.16%
57
413
399
4134
44
188
412
4359
14
39
442
4508
—
10
40
445
4505
45
176
403
4307
60
414
348
3659
Bacteria [Presence] in Urine
87829-8 [36304419]
9.1e-01
6.3e-01
—
—
—
1.2e+00
1.1e+00
cases:5.70%
controls:2.38%
cases:2.41%
controls:1.30%
—
—
—
—
—
—
cases:3.35%
controls:1.05%
cases:10.29%
controls:3.76%
26
108
430
4439
11
59
445
4488
—
—
—
15
47
433
4436
42
153
366
3920
Immunization
WW200 [2001310599]
3.2e+00
—
—
—
—
—
—
cases:6.80%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
31
14
425
4533
—
—
—
—
—
—
oxazepam; oral
N05BA04 [21604569]
6.5e-01
1.1e+00
1.1e+00
—
—
1.1e+00
9.6e-01
cases:5.70%
controls:3.06%
cases:3.95%
controls:1.32%
cases:1.10%
controls:0.35%
—
—
—
—
cases:4.02%
controls:1.41%
cases:8.82%
controls:3.58%
26
139
430
4408
18
60
438
4487
5
16
451
4531
—
—
18
63
430
4420
36
146
372
3927
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
9.0e-01
6.3e-01
—
—
—
1.2e+00
1.1e+00
cases:5.70%
controls:2.40%
cases:2.41%
controls:1.30%
—
—
—
—
—
—
cases:3.35%
controls:1.07%
cases:10.29%
controls:3.83%
26
109
430
4438
11
59
445
4488
—
—
—
15
48
433
4435
42
156
366
3917
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
7.9e-01
1.1e+00
—
—
—
9.6e-01
1.2e+00
cases:8.77%
controls:4.18%
cases:3.73%
controls:1.25%
—
—
—
—
—
—
cases:2.23%
controls:0.87%
cases:11.52%
controls:3.93%
40
190
416
4357
17
57
439
4490
—
—
—
10
39
438
4444
47
160
361
3913
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
2.0e-01
5.7e-01
1.3e+00
—
3.6e-01
6.5e-01
4.9e-01
cases:17.11%
controls:14.45%
cases:12.94%
controls:7.76%
cases:3.95%
controls:1.06%
—
—
cases:1.54%
controls:1.08%
cases:13.62%
controls:7.58%
cases:35.05%
controls:24.80%
78
657
378
3890
59
353
397
4194
18
48
438
4499
—
7
49
448
4496
61
340
387
4143
143
1010
265
3063
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1.6e-01
5.9e-01
1.4e+00
—
7.2e-01
6.5e-01
3.7e-01
cases:22.15%
controls:19.44%
cases:21.93%
controls:13.53%
cases:8.99%
controls:2.46%
—
—
cases:5.27%
controls:2.64%
cases:25.00%
controls:14.83%
cases:42.40%
controls:33.69%
101
884
355
3663
100
615
356
3932
41
112
415
4435
—
24
120
431
4425
112
665
336
3818
173
1372
235
2701
doxycycline; oral, parenteral
J01AA02 [21602800]
6.1e-01
7.2e-01
1.4e+00
—
7.7e-01
7.3e-01
7.5e-01
cases:25.88%
controls:15.92%
cases:8.77%
controls:4.46%
cases:1.75%
controls:0.44%
—
—
cases:1.32%
controls:0.62%
cases:8.71%
controls:4.39%
cases:26.23%
controls:14.44%
118
724
338
3823
40
203
416
4344
8
20
448
4527
—
6
28
449
4517
39
197
409
4286
107
588
301
3485
Hemolysis interference index of Serum or Plasma
46424-8 [3052851]
—
-1.0e+50
—
—
—
—
2.8e+00
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.12%
—
0
5
456
4542
—
—
—
—
8
5
400
4068
Acute pharyngitis, unspecified
J02.9 [45538472]
—
2.8e+00
—
—
—
—
—
—
—
cases:1.75%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
—
8
5
448
4542
—
—
—
—
—
Salmonella sp identified in Stool by Organism specific culture
20955-1 [3004716]
1.4e+00
—
—
—
—
—
1.3e+00
cases:3.73%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.01%
17
42
439
4505
—
—
—
—
—
15
41
393
4032
Depressive episode, unspecified
F32.9 [45571760]
1.2e+00
1.5e+00
—
—
—
1.4e+00
2.1e-01
cases:3.95%
controls:1.25%
cases:2.19%
controls:0.51%
—
—
—
—
—
—
cases:1.79%
controls:0.45%
cases:2.45%
controls:1.99%
18
57
438
4490
10
23
446
4524
—
—
—
8
20
440
4463
10
81
398
3992
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
5.7e-01
8.2e-01
1.5e+00
—
—
7.4e-01
5.1e-01
cases:11.18%
controls:6.62%
cases:6.14%
controls:2.79%
cases:1.97%
controls:0.46%
—
—
—
—
cases:6.25%
controls:3.08%
cases:16.18%
controls:10.36%
51
301
405
4246
28
127
428
4420
9
21
447
4526
—
—
28
138
420
4345
66
422
342
3651
Anoscopy
UJH02 [2001305182]
2.6e+00
—
—
—
—
—
—
cases:1.54%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
—
—
7
5
449
4542
—
—
—
—
—
—
zopiclone; oral
N05CF01 [21604654]
6.7e-01
8.9e-01
1.2e+00
—
—
7.9e-01
1.1e+00
cases:8.11%
controls:4.33%
cases:5.04%
controls:2.13%
cases:1.75%
controls:0.53%
—
—
—
—
cases:4.69%
controls:2.19%
cases:11.03%
controls:4.12%
37
197
419
4350
23
97
433
4450
8
24
448
4523
—
—
21
98
427
4385
45
168
363
3905
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
3.4e-01
6.7e-01
1.2e+00
2.3e+00
7.2e-01
6.8e-01
3.4e-01
cases:23.68%
controls:18.17%
cases:21.49%
controls:12.32%
cases:9.21%
controls:2.84%
cases:1.10%
controls:0.11%
cases:5.71%
controls:2.86%
cases:24.11%
controls:13.81%
cases:38.97%
controls:31.25%
108
826
348
3721
98
560
358
3987
42
129
414
4418
5
5
451
4542
26
130
429
4415
108
619
340
3864
159
1273
249
2800
terbinafine; oral
D01BA02 [21601967]
8.5e-01
8.5e-01
—
—
—
1.7e+00
5.1e-01
cases:6.14%
controls:2.73%
cases:1.54%
controls:0.66%
—
—
—
—
—
—
cases:3.79%
controls:0.71%
cases:5.15%
controls:3.17%
28
124
428
4423
7
30
449
4517
—
—
—
17
32
431
4451
21
129
387
3944
Contact with and exposure to infections with a predominantly sexual mode of transmission
Z20.2 [45609914]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.45%
controls:0.20%
—
—
—
—
—
—
10
8
398
4065
Outpatient Hospital
22 [8756]
7.2e-02
1.1e-01
1.4e+00
—
1.8e+00
7.0e-01
2.2e-01
cases:17.32%
controls:16.32%
cases:5.48%
controls:4.95%
cases:1.75%
controls:0.42%
—
—
cases:3.30%
controls:0.57%
cases:7.37%
controls:3.81%
cases:17.16%
controls:14.19%
79
742
377
3805
25
225
431
4322
8
19
448
4528
—
15
26
440
4519
33
171
415
4312
70
578
338
3495
hydrocortisone
S02BA01 [21605166]
2.9e-01
7.0e-01
2.5e+00
—
-1.0e+50
8.8e-01
2.7e-01
cases:6.58%
controls:4.99%
cases:2.85%
controls:1.43%
cases:1.54%
controls:0.13%
—
—
cases:0.00%
controls:0.20%
cases:3.79%
controls:1.61%
cases:7.11%
controls:5.50%
30
227
426
4320
13
65
443
4482
7
6
449
4541
—
0
9
455
4536
17
72
431
4411
29
224
379
3849
testosterone; oral, parenteral, rectal, sublingual, transdermal
G03BA03 [21602510]
1.3e+00
1.1e+00
—
—
—
9.3e-01
1.2e+00
cases:2.63%
controls:0.75%
cases:1.97%
controls:0.64%
—
—
—
—
—
—
cases:2.01%
controls:0.80%
cases:3.68%
controls:1.18%
12
34
444
4513
9
29
447
4518
—
—
—
9
36
439
4447
15
48
393
4025
Psychiatry
26 [38004469]
7.6e-01
4.5e-01
7.4e-01
-1.0e+50
6.8e-01
8.7e-01
8.1e-01
cases:12.72%
controls:6.40%
cases:5.92%
controls:3.85%
cases:3.07%
controls:1.50%
cases:0.00%
controls:0.13%
cases:3.30%
controls:1.69%
cases:8.04%
controls:3.55%
cases:13.97%
controls:6.75%
58
291
398
4256
27
175
429
4372
14
68
442
4479
0
6
456
4541
15
77
440
4468
36
159
412
4324
57
275
351
3798
Curettage of cervix uteri
LDA10 [2001306655]
—
—
—
1.0e+50
—
—
2.3e+00
—
—
—
—
—
—
cases:1.54%
controls:0.00%
—
—
—
—
cases:1.72%
controls:0.17%
—
—
—
7
0
449
4547
—
—
7
7
401
4066
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
4.6e-01
7.3e-01
—
—
9.7e-01
1.3e+00
9.7e-01
cases:10.96%
controls:7.21%
cases:5.70%
controls:2.84%
—
—
—
—
cases:1.10%
controls:0.42%
cases:8.93%
controls:2.70%
cases:23.28%
controls:10.29%
50
328
406
4219
26
129
430
4418
—
—
5
19
450
4526
40
121
408
4362
95
419
313
3654
zolpidem; oral
N05CF02 [21604655]
9.1e-01
1.5e-01
—
—
—
1.3e+00
7.0e-01
cases:5.04%
controls:2.09%
cases:1.10%
controls:0.95%
—
—
—
—
—
—
cases:3.13%
controls:0.91%
cases:4.17%
controls:2.11%
23
95
433
4452
5
43
451
4504
—
—
—
14
41
434
4442
17
86
391
3987
Emotionally unstable personality disorder, impulsive
F60.30 [2000502022]
2.2e+00
—
—
—
—
—
2.1e+00
cases:1.32%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
cases:1.23%
controls:0.15%
6
7
450
4540
—
—
—
—
—
5
6
403
4067
Gliadin peptide IgA Ab [Units/volume] in Serum by Immunoassay
63453-5 [40766183]
2.2e+00
-1.0e+50
—
—
—
—
—
cases:1.32%
controls:0.15%
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
6
7
450
4540
0
7
456
4540
—
—
—
—
—
FEV1 --post bronchodilation
20155-8 [3023550]
1.1e+00
—
—
—
—
—
2.1e+00
cases:1.54%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.25%
7
23
449
4524
—
—
—
—
—
8
10
400
4063
FVC percent change Respiratory system
69982-7 [42868471]
1.1e+00
—
—
—
—
—
2.1e+00
cases:1.54%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.25%
7
23
449
4524
—
—
—
—
—
8
10
400
4063
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
1.1e+00
—
—
—
—
—
2.1e+00
cases:1.54%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.25%
7
23
449
4524
—
—
—
—
—
8
10
400
4063
FEV1/FVC --post bronchodilation
69970-2 [42868459]
1.1e+00
—
—
—
—
—
2.1e+00
cases:1.54%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.25%
7
23
449
4524
—
—
—
—
—
8
10
400
4063
FEV1 percent change
69983-5 [42868472]
1.1e+00
—
—
—
—
—
2.1e+00
cases:1.54%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.25%
7
23
449
4524
—
—
—
—
—
8
10
400
4063
Person consulting for explanation of investigation findings
Z71.2 [45552100]
1.1e+00
7.0e-01
—
—
—
9.5e-01
1.0e+00
cases:6.36%
controls:2.31%
cases:1.32%
controls:0.66%
—
—
—
—
—
—
cases:2.46%
controls:0.96%
cases:8.33%
controls:3.14%
29
105
427
4442
6
30
450
4517
—
—
—
11
43
437
4440
34
128
374
3945
Hepatitis A virus Ab [Presence] in Serum
20575-7 [3016650]
1.3e+00
—
—
—
—
2.0e+00
2.1e+00
cases:1.10%
controls:0.31%
—
—
—
—
—
—
—
—
cases:1.12%
controls:0.16%
cases:3.43%
controls:0.44%
5
14
451
4533
—
—
—
—
5
7
443
4476
14
18
394
4055
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
2.6e-01
5.4e-01
1.0e+00
—
5.2e-01
4.8e-01
2.6e-01
cases:19.30%
controls:15.57%
cases:15.79%
controls:9.83%
cases:3.73%
controls:1.34%
—
—
cases:1.98%
controls:1.19%
cases:16.29%
controls:10.80%
cases:35.78%
controls:29.95%
88
708
368
3839
72
447
384
4100
17
61
439
4486
—
9
54
446
4491
73
484
375
3999
146
1220
262
2853
alprostadil; parenteral
C01EA01 [21600362]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.72%
controls:0.22%
—
—
—
—
—
—
7
9
401
4064
Procedure duration 60 to 89 minutes
ZXE11 [2001311402]
—
-1.0e+50
—
—
—
—
2.1e+00
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
—
—
cases:2.45%
controls:0.32%
—
0
12
456
4535
—
—
—
—
10
13
398
4060
Inpatient Hospital
21 [8717]
1.1e-01
4.2e-02
1.0e+00
—
1.3e+00
7.0e-01
2.3e-01
cases:25.22%
controls:23.18%
cases:7.46%
controls:7.17%
cases:2.41%
controls:0.88%
—
—
cases:3.52%
controls:0.95%
cases:12.28%
controls:6.51%
cases:23.04%
controls:19.25%
115
1054
341
3493
34
326
422
4221
11
40
445
4507
—
16
43
439
4502
55
292
393
4191
94
784
314
3289
Other and unspecified abdominal pain
R10.4 [45568113]
4.6e-01
1.2e+00
—
—
—
9.7e-01
8.7e-01
cases:5.70%
controls:3.67%
cases:3.29%
controls:1.06%
—
—
—
—
—
—
cases:3.13%
controls:1.20%
cases:9.56%
controls:4.25%
26
167
430
4380
15
48
441
4499
—
—
—
14
54
434
4429
39
173
369
3900
Persons encountering health services in other circumstances
Z76 [45537674]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.20%
—
—
—
—
—
—
6
8
402
4065
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
2.5e-01
5.3e-01
1.0e+00
—
5.0e-01
4.7e-01
2.8e-01
cases:19.08%
controls:15.48%
cases:15.57%
controls:9.81%
cases:3.73%
controls:1.36%
—
—
cases:1.98%
controls:1.21%
cases:16.07%
controls:10.73%
cases:35.78%
controls:29.61%
87
704
369
3843
71
446
385
4101
17
62
439
4485
—
9
55
446
4490
72
481
376
4002
146
1206
262
2867
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
1.3e+00
—
—
—
—
—
2.0e+00
cases:1.97%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.27%
9
24
447
4523
—
—
—
—
—
8
11
400
4062
FEV1
20150-9 [3024653]
1.3e+00
—
—
—
—
—
2.0e+00
cases:1.97%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.27%
9
24
447
4523
—
—
—
—
—
8
11
400
4062
FEV1/FVC
19926-5 [3011505]
1.3e+00
—
—
—
—
—
2.0e+00
cases:1.97%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.27%
9
24
447
4523
—
—
—
—
—
8
11
400
4062
alprostadil; implant, parenteral
G04BE01 [21602646]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.27%
—
—
—
—
—
—
8
11
400
4062
Deposits [accretions] on teeth betel
K03.65 [2000502690]
8.9e-01
8.5e-01
—
—
-1.0e+50
1.1e+00
1.1e+00
cases:4.82%
controls:2.05%
cases:1.54%
controls:0.66%
—
—
—
—
cases:0.00%
controls:0.11%
cases:2.23%
controls:0.78%
cases:7.35%
controls:2.55%
22
93
434
4454
7
30
449
4517
—
—
0
5
455
4540
10
35
438
4448
30
104
378
3969
Social worker
Z2446 [2001311559]
1.1e+00
—
—
—
—
—
2.0e+00
cases:1.75%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
cases:2.45%
controls:0.34%
8
26
448
4521
—
—
—
—
—
10
14
398
4059
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
-8.9e-01
-1.8e-01
—
—
2.0e+00
6.6e-02
-4.5e-01
cases:1.75%
controls:4.16%
cases:1.54%
controls:1.83%
—
—
—
—
cases:1.54%
controls:0.22%
cases:1.79%
controls:1.67%
cases:3.68%
controls:5.65%
8
189
448
4358
7
83
449
4464
—
—
7
10
448
4535
8
75
440
4408
15
230
393
3843
Dental calculus supragingival
K03.64 [2000502689]
3.2e-01
5.7e-02
—
—
—
1.1e+00
7.4e-01
cases:4.82%
controls:3.56%
cases:1.54%
controls:1.45%
—
—
—
—
—
—
cases:3.79%
controls:1.32%
cases:9.07%
controls:4.54%
22
162
434
4385
7
66
449
4481
—
—
—
17
59
431
4424
37
185
371
3888
Pain localized to other parts of lower abdomen
R10.3 [45534426]
5.1e-01
1.1e+00
—
—
—
1.8e+00
5.3e-01
cases:3.07%
controls:1.87%
cases:1.54%
controls:0.53%
—
—
—
—
—
—
cases:2.68%
controls:0.45%
cases:4.17%
controls:2.50%
14
85
442
4462
7
24
449
4523
—
—
—
12
20
436
4463
17
102
391
3971
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
4.1e-01
1.1e+00
—
—
—
8.0e-01
7.3e-01
cases:1.97%
controls:1.32%
cases:2.85%
controls:0.99%
—
—
—
—
—
—
cases:3.13%
controls:1.43%
cases:11.76%
controls:6.06%
9
60
447
4487
13
45
443
4502
—
—
—
14
64
434
4419
48
247
360
3826
Gastroenteritis presumed infection
D73 [2002000371]
—
-1.0e+50
—
—
—
—
1.7e+00
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
cases:2.45%
controls:0.44%
—
0
6
456
4541
—
—
—
—
10
18
398
4055
Mixed anxiety and depressive disorder
F41.2 [45566845]
1.1e+00
1.7e+00
—
—
—
1.0e+00
2.4e-01
cases:2.41%
controls:0.81%
cases:2.19%
controls:0.40%
—
—
—
—
—
—
cases:1.12%
controls:0.40%
cases:1.72%
controls:1.35%
11
37
445
4510
10
18
446
4529
—
—
—
5
18
443
4465
7
55
401
4018
fusidic acid
D09AA02 [21602265]
6.4e-01
1.7e+00
—
—
—
8.7e-01
6.6e-01
cases:3.95%
controls:2.11%
cases:2.63%
controls:0.48%
—
—
—
—
—
—
cases:1.79%
controls:0.76%
cases:5.88%
controls:3.12%
18
96
438
4451
12
22
444
4525
—
—
—
8
34
440
4449
24
127
384
3946
fusidic acid; ointment
D06AX01 [21602062]
6.4e-01
1.7e+00
—
—
—
8.7e-01
6.6e-01
cases:3.95%
controls:2.11%
cases:2.63%
controls:0.48%
—
—
—
—
—
—
cases:1.79%
controls:0.76%
cases:5.88%
controls:3.12%
18
96
438
4451
12
22
444
4525
—
—
—
8
34
440
4449
24
127
384
3946
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
5.1e-01
4.2e-01
1.7e+00
—
—
6.6e-01
5.9e-01
cases:7.89%
controls:4.90%
cases:3.07%
controls:2.05%
cases:1.75%
controls:0.33%
—
—
—
—
cases:3.79%
controls:2.01%
cases:8.33%
controls:4.79%
36
223
420
4324
14
93
442
4454
8
15
448
4532
—
—
17
90
431
4393
34
195
374
3878
chloramphenicol
S01AA01 [21603554]
5.9e-01
7.6e-01
—
—
-1.0e+50
1.0e+00
6.5e-01
cases:8.55%
controls:4.95%
cases:3.95%
controls:1.89%
—
—
—
—
cases:0.00%
controls:0.35%
cases:4.69%
controls:1.72%
cases:13.24%
controls:7.39%
39
225
417
4322
18
86
438
4461
—
—
0
16
455
4529
21
77
427
4406
54
301
354
3772
chloramphenicol
S03AA08 [21605197]
5.9e-01
7.6e-01
—
—
-1.0e+50
1.0e+00
6.5e-01
cases:8.55%
controls:4.95%
cases:3.95%
controls:1.89%
—
—
—
—
cases:0.00%
controls:0.35%
cases:4.69%
controls:1.72%
cases:13.24%
controls:7.39%
39
225
417
4322
18
86
438
4461
—
—
0
16
455
4529
21
77
427
4406
54
301
354
3772
venlafaxine; oral
N06AX16 [21604745]
6.2e-01
8.7e-01
1.7e+00
—
—
1.0e+00
7.2e-01
cases:3.29%
controls:1.80%
cases:2.63%
controls:1.12%
cases:1.97%
controls:0.37%
—
—
—
—
cases:2.90%
controls:1.05%
cases:4.17%
controls:2.06%
15
82
441
4465
12
51
444
4496
9
17
447
4530
—
—
13
47
435
4436
17
84
391
3989
Campylobacter sp identified in Tissue by Organism specific culture
20740-7 [3006418]
1.7e+00
—
—
—
—
—
1.6e+00
cases:2.19%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:1.72%
controls:0.37%
10
19
446
4528
—
—
—
—
—
7
15
401
4058
Yersinia sp identified in Stool by Organism specific culture
28549-4 [3014765]
1.7e+00
—
—
—
—
—
1.5e+00
cases:2.19%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:1.72%
controls:0.39%
10
19
446
4528
—
—
—
—
—
7
16
401
4057
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4.0e-01
4.6e-01
1.7e+00
—
7.8e-01
3.7e-01
3.8e-01
cases:12.28%
controls:8.58%
cases:6.80%
controls:4.40%
cases:3.29%
controls:0.64%
—
—
cases:1.76%
controls:0.81%
cases:7.14%
controls:5.06%
cases:19.61%
controls:14.31%
56
390
400
4157
31
200
425
4347
15
29
441
4518
—
8
37
447
4508
32
227
416
4256
80
583
328
3490
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
6.7e-01
5.3e-01
—
—
1.6e+00
9.9e-01
6.7e-01
cases:6.80%
controls:3.58%
cases:2.85%
controls:1.69%
—
—
—
—
cases:1.10%
controls:0.22%
cases:3.79%
controls:1.45%
cases:10.29%
controls:5.55%
31
163
425
4384
13
77
443
4470
—
—
5
10
450
4535
17
65
431
4418
42
226
366
3847
Failure of genital response
F52.2 [45547715]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.39%
—
—
—
—
—
—
8
16
400
4057
Flexible sigmoidoscopy with biopsy
UJF45 [2001305031]
1.6e+00
—
—
—
—
—
1.6e+00
cases:1.97%
controls:0.40%
—
—
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.42%
9
18
447
4529
—
—
—
—
—
8
17
400
4056
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
7.8e-01
7.4e-01
—
—
—
9.9e-01
8.2e-01
cases:6.14%
controls:2.93%
cases:2.85%
controls:1.39%
—
—
—
—
—
—
cases:3.35%
controls:1.27%
cases:10.29%
controls:4.81%
28
133
428
4414
13
63
443
4484
—
—
—
15
57
433
4426
42
196
366
3877
Exposure to unspecified factor
X59 [45756412]
5.2e-01
1.6e+00
—
—
-1.0e+50
1.3e+00
2.8e-01
cases:3.73%
controls:2.24%
cases:2.19%
controls:0.46%
—
—
—
—
cases:0.00%
controls:0.11%
cases:2.01%
controls:0.58%
cases:3.19%
controls:2.43%
17
102
439
4445
10
21
446
4526
—
—
0
5
455
4540
9
26
439
4457
13
99
395
3974
Ileoscopy through colon
UJF30 [2001305028]
1.0e+00
—
—
—
—
—
1.5e+00
cases:1.75%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:2.70%
controls:0.59%
8
29
448
4518
—
—
—
—
—
11
24
397
4049
Ova and parasites identified in Stool by Light microscopy
10704-5 [3003327]
1.2e+00
—
—
—
—
2.3e+00
1.5e+00
cases:1.54%
controls:0.46%
—
—
—
—
—
—
—
—
cases:1.12%
controls:0.11%
cases:3.43%
controls:0.76%
7
21
449
4526
—
—
—
—
5
5
443
4478
14
31
394
4042
Extensive body CT
JN4BD [2001310899]
1.5e+00
—
—
—
—
—
1.4e+00
cases:2.19%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
cases:1.72%
controls:0.44%
10
22
446
4525
—
—
—
—
—
7
18
401
4055
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
2.3e-01
4.7e-01
1.0e+00
—
4.1e-01
4.1e-01
2.7e-01
cases:19.30%
controls:15.90%
cases:15.57%
controls:10.38%
cases:3.95%
controls:1.43%
—
—
cases:1.98%
controls:1.32%
cases:16.29%
controls:11.47%
cases:36.76%
controls:30.79%
88
723
368
3824
71
472
385
4075
18
65
438
4482
—
9
60
446
4485
73
514
375
3969
150
1254
258
2819
mirtazapine; oral
N06AX11 [21604740]
6.9e-01
3.6e-01
—
—
—
5.8e-01
8.1e-01
cases:7.46%
controls:3.89%
cases:3.29%
controls:2.31%
—
—
—
—
—
—
cases:3.79%
controls:2.16%
cases:10.54%
controls:4.96%
34
177
422
4370
15
105
441
4442
—
—
—
17
97
431
4386
43
202
365
3871
Fungus identified in Specimen by Culture
580-1 [3000494]
4.9e-01
—
—
—
—
1.5e+00
6.1e-01
cases:1.54%
controls:0.95%
—
—
—
—
—
—
—
—
cases:2.01%
controls:0.47%
cases:2.94%
controls:1.62%
7
43
449
4504
—
—
—
—
9
21
439
4462
12
66
396
4007
varenicline; oral
N07BA03 [21604819]
8.9e-01
—
—
—
—
—
1.5e+00
cases:1.54%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.52%
7
29
449
4518
—
—
—
—
—
9
21
399
4052
clindamycin; oral, parenteral
J01FF01 [21602985]
4.8e-01
1.2e+00
—
—
—
1.4e+00
3.3e-01
cases:4.39%
controls:2.77%
cases:1.97%
controls:0.59%
—
—
—
—
—
—
cases:2.46%
controls:0.60%
cases:4.41%
controls:3.22%
20
126
436
4421
9
27
447
4520
—
—
—
11
27
437
4456
18
131
390
3942
One hour or less
ZXE00 [2001311394]
2.0e-01
8.1e-01
—
—
—
1.4e+00
5.2e-01
cases:5.48%
controls:4.53%
cases:2.19%
controls:0.99%
—
—
—
—
—
—
cases:2.90%
controls:0.74%
cases:5.39%
controls:3.27%
25
206
431
4341
10
45
446
4502
—
—
—
13
33
435
4450
22
133
386
3940
androstanolone
G03BB02 [21602513]
1.4e+00
1.3e+00
—
—
—
9.6e-01
1.4e+00
cases:1.75%
controls:0.42%
cases:1.54%
controls:0.42%
—
—
—
—
—
—
cases:1.56%
controls:0.60%
cases:3.19%
controls:0.81%
8
19
448
4528
7
19
449
4528
—
—
—
7
27
441
4456
13
33
395
4040
Throat symptom/complaint
R21 [2002000891]
4.2e-01
1.4e+00
—
—
—
9.9e-01
6.2e-01
cases:4.17%
controls:2.77%
cases:2.85%
controls:0.73%
—
—
—
—
—
—
cases:1.79%
controls:0.67%
cases:5.88%
controls:3.27%
19
126
437
4421
13
33
443
4514
—
—
—
8
30
440
4453
24
133
384
3940
tadalafil; oral
G04BE08 [21602653]
7.3e-01
1.0e+00
—
—
—
8.6e-01
1.4e+00
cases:1.54%
controls:0.75%
cases:1.10%
controls:0.40%
—
—
—
—
—
—
cases:1.56%
controls:0.67%
cases:6.37%
controls:1.72%
7
34
449
4513
5
18
451
4529
—
—
—
7
30
441
4453
26
70
382
4003
betamethasone
S03BA03 [21605203]
6.2e-01
—
—
—
—
1.4e+00
4.1e-01
cases:3.07%
controls:1.67%
—
—
—
—
—
—
—
—
cases:2.46%
controls:0.65%
cases:2.94%
controls:1.96%
14
76
442
4471
—
—
—
—
11
29
437
4454
12
80
396
3993
androstanolone
A14AA01 [21600917]
1.3e+00
1.2e+00
—
—
—
9.3e-01
1.3e+00
cases:1.75%
controls:0.46%
cases:1.54%
controls:0.48%
—
—
—
—
—
—
cases:1.56%
controls:0.62%
cases:3.19%
controls:0.88%
8
21
448
4526
7
22
449
4525
—
—
—
7
28
441
4455
13
36
395
4037
Testosterone Free [Moles/volume] in Serum or Plasma by calculation
96559-0 [36032269]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.94%
controls:0.88%
—
—
—
—
—
—
12
36
396
4037
mesalazine; oral, rectal
A07EC02 [21600664]
1.2e+00
7.3e-01
—
—
—
7.3e-01
6.8e-01
cases:2.85%
controls:0.90%
cases:1.54%
controls:0.75%
—
—
—
—
—
—
cases:1.56%
controls:0.76%
cases:1.96%
controls:1.01%
13
41
443
4506
7
34
449
4513
—
—
—
7
34
441
4449
8
41
400
4032
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
3.2e-01
—
—
—
—
—
1.2e+00
cases:1.54%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
cases:3.43%
controls:1.10%
7
51
449
4496
—
—
—
—
—
14
45
394
4028
Sex hormone binding globulin [Moles/volume] in Serum or Plasma
13967-5 [3004248]
1.3e-01
—
—
—
—
3.9e-01
1.1e+00
cases:1.10%
controls:0.97%
—
—
—
—
—
—
—
—
cases:1.12%
controls:0.76%
cases:3.68%
controls:1.20%
5
44
451
4503
—
—
—
—
5
34
443
4449
15
49
393
4024
fluconazole; oral, parenteral
J02AC01 [21603080]
4.8e-01
1.1e+00
—
—
1.8e+00
9.0e-01
3.0e-01
cases:7.89%
controls:5.04%
cases:3.73%
controls:1.23%
—
—
—
—
cases:1.32%
controls:0.22%
cases:3.13%
controls:1.29%
cases:6.37%
controls:4.81%
36
229
420
4318
17
56
439
4491
—
—
6
10
449
4535
14
58
434
4425
26
196
382
3877
citalopram; oral, parenteral
N06AB04 [21604712]
1.1e+00
7.4e-01
—
—
—
6.3e-01
5.6e-01
cases:5.70%
controls:1.91%
cases:2.85%
controls:1.39%
—
—
—
—
—
—
cases:2.23%
controls:1.20%
cases:4.41%
controls:2.58%
26
87
430
4460
13
63
443
4484
—
—
—
10
54
438
4429
18
105
390
3968
quetiapine; oral
N05AH04 [21604544]
4.5e-01
5.9e-01
—
—
8.9e-01
8.0e-01
1.1e+00
cases:4.82%
controls:3.12%
cases:3.73%
controls:2.11%
—
—
—
—
cases:1.54%
controls:0.64%
cases:4.46%
controls:2.05%
cases:10.05%
controls:3.51%
22
142
434
4405
17
96
439
4451
—
—
7
29
448
4516
20
92
428
4391
41
143
367
3930
Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
546-2 [3024135]
6.5e-01
1.1e+00
—
—
—
6.1e-01
4.9e-01
cases:6.58%
controls:3.56%
cases:3.51%
controls:1.23%
—
—
—
—
—
—
cases:1.79%
controls:0.98%
cases:7.60%
controls:4.79%
30
162
426
4385
16
56
440
4491
—
—
—
8
44
440
4439
31
195
377
3878
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
7.6e-01
1.1e+00
—
—
—
1.4e+00
1.1e+00
cases:2.41%
controls:1.14%
cases:1.97%
controls:0.68%
—
—
—
—
—
—
cases:2.01%
controls:0.51%
cases:6.37%
controls:2.28%
11
52
445
4495
9
31
447
4516
—
—
—
9
23
439
4460
26
93
382
3980
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
1.0e+00
—
—
—
—
—
6.2e-01
cases:3.29%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
cases:2.70%
controls:1.47%
15
54
441
4493
—
—
—
—
—
11
60
397
4013
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
3.6e-01
4.0e-01
1.0e+00
—
4.8e-01
3.4e-01
3.4e-01
cases:15.79%
controls:11.61%
cases:11.84%
controls:8.29%
cases:3.51%
controls:1.28%
—
—
cases:1.98%
controls:1.23%
cases:13.17%
controls:9.70%
cases:31.62%
controls:24.85%
72
528
384
4019
54
377
402
4170
16
58
440
4489
—
9
56
446
4489
59
435
389
4048
129
1012
279
3061
beclometasone; nasal
R01AD01 [21605043]
5.3e-01
1.1e+00
—
—
—
1.2e+00
1.0e+00
cases:2.19%
controls:1.30%
cases:1.75%
controls:0.57%
—
—
—
—
—
—
cases:1.56%
controls:0.47%
cases:3.43%
controls:1.25%
10
59
446
4488
8
26
448
4521
—
—
—
7
21
441
4462
14
51
394
4022
Thorax X-ray examination
GD1AA [2001303617]
6.3e-01
-2.7e-01
—
—
-1.0e+50
1.0e+00
6.1e-01
cases:7.68%
controls:4.24%
cases:1.54%
controls:2.00%
—
—
—
—
cases:0.00%
controls:0.11%
cases:3.35%
controls:1.25%
cases:8.33%
controls:4.69%
35
193
421
4354
7
91
449
4456
—
—
0
5
455
4540
15
56
433
4427
34
191
374
3882
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
9.5e-01
1.0e+00
—
—
—
1.4e+00
9.8e-01
cases:2.41%
controls:0.95%
cases:1.97%
controls:0.70%
—
—
—
—
—
—
cases:2.23%
controls:0.58%
cases:6.62%
controls:2.60%
11
43
445
4504
9
32
447
4515
—
—
—
10
26
438
4457
27
106
381
3967
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
4.7e-01
—
—
—
—
1.0e+00
9.6e-01
cases:2.41%
controls:1.52%
—
—
—
—
—
—
—
—
cases:1.34%
controls:0.49%
cases:4.90%
controls:1.94%
11
69
445
4478
—
—
—
—
6
22
442
4461
20
79
388
3994
Simple examination of mouth
SAA01 [2001310274]
2.0e-01
3.0e-01
6.0e-01
—
—
5.6e-01
3.9e-01
cases:18.86%
controls:16.03%
cases:9.65%
controls:7.30%
cases:1.32%
controls:0.73%
—
—
—
—
cases:12.50%
controls:7.52%
cases:31.62%
controls:23.82%
86
729
370
3818
44
332
412
4215
6
33
450
4514
—
—
56
337
392
4146
129
970
279
3103
Pneumonia, unspecified
J18.9 [45601123]
9.4e-01
—
—
—
-1.0e+50
—
3.2e-01
cases:3.95%
controls:1.58%
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
cases:3.68%
controls:2.70%
18
72
438
4475
—
—
—
0
5
455
4540
—
15
110
393
3963
Issue of repeat prescription
Z76.0 [45542456]
8.6e-01
5.6e-01
—
—
-1.0e+50
1.1e+00
9.2e-01
cases:2.41%
controls:1.03%
cases:1.54%
controls:0.88%
—
—
—
—
cases:0.00%
controls:0.11%
cases:2.46%
controls:0.87%
cases:9.07%
controls:3.81%
11
47
445
4500
7
40
449
4507
—
—
0
5
455
4540
11
39
437
4444
37
155
371
3918
Periodontal treatment by dental hygienist, extensive
SDE03 [2001310351]
2.6e-01
—
—
—
—
1.1e+00
9.1e-01
cases:3.51%
controls:2.73%
—
—
—
—
—
—
—
—
cases:1.56%
controls:0.54%
cases:6.86%
controls:2.87%
16
124
440
4423
—
—
—
—
7
24
441
4459
28
117
380
3956
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
—
—
—
—
-1.0e+50
8.1e-01
9.0e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
cases:1.34%
controls:0.60%
cases:5.39%
controls:2.26%
—
—
—
—
0
7
455
4538
6
27
442
4456
22
92
386
3981
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
6.2e-01
4.2e-01
—
—
—
8.8e-01
8.9e-01
cases:3.95%
controls:2.16%
cases:1.54%
controls:1.01%
—
—
—
—
—
—
cases:2.23%
controls:0.94%
cases:5.39%
controls:2.28%
18
98
438
4449
7
46
449
4501
—
—
—
10
42
438
4441
22
93
386
3980
temazepam; oral
N05CD07 [21604642]
9.3e-02
7.5e-01
—
—
—
9.8e-01
8.9e-01
cases:2.19%
controls:2.00%
cases:1.97%
controls:0.95%
—
—
—
—
—
—
cases:2.46%
controls:0.94%
cases:5.39%
controls:2.28%
10
91
446
4456
9
43
447
4504
—
—
—
11
42
437
4441
22
93
386
3980
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
3.1e-01
3.4e-01
8.8e-01
—
4.4e-01
2.8e-01
1.8e-01
cases:40.79%
controls:33.54%
cases:17.98%
controls:13.48%
cases:5.26%
controls:2.24%
—
—
cases:3.52%
controls:2.29%
cases:19.64%
controls:15.59%
cases:42.16%
controls:37.91%
186
1525
270
3022
82
613
374
3934
24
102
432
4445
—
16
104
439
4441
88
699
360
3784
172
1544
236
2529
ibuprofen
R02AX02 [1588667]
3.1e-01
3.4e-01
8.8e-01
—
4.4e-01
2.8e-01
1.8e-01
cases:40.79%
controls:33.54%
cases:17.98%
controls:13.48%
cases:5.26%
controls:2.24%
—
—
cases:3.52%
controls:2.29%
cases:19.64%
controls:15.59%
cases:42.16%
controls:37.91%
186
1525
270
3022
82
613
374
3934
24
102
432
4445
—
16
104
439
4441
88
699
360
3784
172
1544
236
2529
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
8.3e-01
9.5e-01
—
—
—
9.3e-01
8.8e-01
cases:3.51%
controls:1.56%
cases:1.97%
controls:0.77%
—
—
—
—
—
—
cases:2.01%
controls:0.80%
cases:6.37%
controls:2.75%
16
71
440
4476
9
35
447
4512
—
—
—
9
36
439
4447
26
112
382
3961
Upper respiratory infection acute
R74 [2002000942]
5.4e-01
4.6e-01
—
—
—
7.8e-01
8.5e-01
cases:8.11%
controls:4.90%
cases:2.85%
controls:1.83%
—
—
—
—
—
—
cases:4.02%
controls:1.87%
cases:14.46%
controls:6.75%
37
223
419
4324
13
83
443
4464
—
—
—
18
84
430
4399
59
275
349
3798
Osmolality of Urine
2695-5 [3026782]
6.0e-01
—
—
—
—
—
8.3e-01
cases:3.73%
controls:2.09%
—
—
—
—
—
—
—
—
—
—
cases:5.15%
controls:2.31%
17
95
439
4452
—
—
—
—
—
21
94
387
3979
CBC panel - Blood by Automated count
58410-2 [40761511]
3.7e-02
1.9e-01
8.2e-01
—
1.8e-01
1.3e-01
8.3e-02
cases:19.96%
controls:19.38%
cases:14.69%
controls:12.47%
cases:5.04%
controls:2.29%
—
—
cases:2.64%
controls:2.22%
cases:14.06%
controls:12.51%
cases:33.82%
controls:31.99%
91
881
365
3666
67
567
389
3980
23
104
433
4443
—
12
101
443
4444
63
561
385
3922
138
1303
270
2770
Other specified counselling
Z71.8 [45581061]
1.3e-01
5.2e-01
1.4e+00
—
—
9.9e-01
8.1e-01
cases:2.85%
controls:2.51%
cases:1.97%
controls:1.19%
cases:1.10%
controls:0.29%
—
—
—
—
cases:2.90%
controls:1.09%
cases:11.03%
controls:5.21%
13
114
443
4433
9
54
447
4493
5
13
451
4534
—
—
13
49
435
4434
45
212
363
3861
Physiotherapy
R4110 [2001310233]
5.8e-01
1.5e-01
—
—
—
8.2e-01
8.1e-01
cases:4.39%
controls:2.51%
cases:1.10%
controls:0.95%
—
—
—
—
—
—
cases:2.01%
controls:0.89%
cases:5.64%
controls:2.58%
20
114
436
4433
5
43
451
4504
—
—
—
9
40
439
4443
23
105
385
3968
roxithromycin; oral
J01FA06 [21602974]
7.8e-01
—
—
—
—
3.6e-01
5.4e-01
cases:7.89%
controls:3.78%
—
—
—
—
—
—
—
—
cases:1.12%
controls:0.78%
cases:4.66%
controls:2.77%
36
172
420
4375
—
—
—
—
5
35
443
4448
19
113
389
3960
Testosterone [Moles/volume] in Serum or Plasma
14913-8 [3017446]
2.2e-01
1.8e-01
-1.0e+50
—
-1.0e+50
2.6e-01
7.7e-01
cases:2.19%
controls:1.76%
cases:1.32%
controls:1.10%
cases:0.00%
controls:0.13%
—
—
cases:0.00%
controls:0.18%
cases:1.79%
controls:1.38%
cases:6.86%
controls:3.29%
10
80
446
4467
6
50
450
4497
0
6
456
4541
—
0
8
455
4537
8
62
440
4421
28
134
380
3939
Health maint/preventive medicine
A98 [2002000231]
1.7e-01
1.1e-01
6.1e-01
—
2.3e-01
4.0e-01
3.5e-01
cases:26.97%
controls:23.73%
cases:17.76%
controls:16.25%
cases:4.39%
controls:2.44%
—
—
cases:2.86%
controls:2.29%
cases:23.21%
controls:16.89%
cases:47.06%
controls:38.55%
123
1079
333
3468
81
739
375
3808
20
111
436
4436
—
13
104
442
4441
104
757
344
3726
192
1570
216
2503
Chronic apical periodontitis
K04.5 [45586691]
-1.8e-01
—
—
—
—
5.8e-01
7.4e-01
cases:1.97%
controls:2.35%
—
—
—
—
—
—
—
—
cases:1.79%
controls:1.00%
cases:7.35%
controls:3.66%
9
107
447
4440
—
—
—
—
8
45
440
4438
30
149
378
3924
Upper gastrointestinal surgery
106 [44777669]
5.4e-01
7.1e-01
—
—
—
8.5e-01
7.0e-01
cases:8.55%
controls:5.19%
cases:4.17%
controls:2.09%
—
—
—
—
—
—
cases:4.24%
controls:1.85%
cases:11.03%
controls:5.82%
39
236
417
4311
19
95
437
4452
—
—
—
19
83
429
4400
45
237
363
3836
metronidazole; oral, rectal
P01AB01 [21604857]
4.7e-01
3.4e-01
2.0e+00
—
—
5.9e-01
6.8e-01
cases:7.46%
controls:4.82%
cases:1.97%
controls:1.41%
cases:1.10%
controls:0.15%
—
—
—
—
cases:2.23%
controls:1.25%
cases:10.54%
controls:5.65%
34
219
422
4328
9
64
447
4483
5
7
451
4540
—
—
10
56
438
4427
43
230
365
3843
Dental examination
Z01.2 [45581002]
5.3e-01
1.4e-01
—
—
—
5.1e-01
6.3e-01
cases:9.43%
controls:5.78%
cases:2.41%
controls:2.11%
—
—
—
—
—
—
cases:4.02%
controls:2.45%
cases:14.71%
controls:8.42%
43
263
413
4284
11
96
445
4451
—
—
—
18
110
430
4373
60
343
348
3730
mometasone; nasal
R01AD09 [21605051]
-5.7e-02
1.8e-01
—
—
—
2.0e-01
6.3e-01
cases:6.36%
controls:6.71%
cases:2.85%
controls:2.40%
—
—
—
—
—
—
cases:3.13%
controls:2.57%
cases:13.24%
controls:7.54%
29
305
427
4242
13
109
443
4438
—
—
—
14
115
434
4368
54
307
354
3766
General Practice
1 [38004446]
2.2e-01
3.4e-01
—
1.0e+50
9.2e-01
7.2e-01
6.1e-01
cases:9.87%
controls:8.09%
cases:3.73%
controls:2.68%
—
—
cases:1.32%
controls:0.00%
cases:1.10%
controls:0.44%
cases:5.36%
controls:2.68%
cases:15.69%
controls:9.16%
45
368
411
4179
17
122
439
4425
—
6
0
450
4547
5
20
450
4525
24
120
424
4363
64
373
344
3700
Intraoral radiographic dental examination
EB1AA [2001301903]
2.3e-01
-5.4e-02
—
—
—
4.4e-01
5.3e-01
cases:11.84%
controls:9.63%
cases:3.51%
controls:3.69%
—
—
—
—
—
—
cases:5.58%
controls:3.68%
cases:18.87%
controls:12.03%
54
438
402
4109
16
168
440
4379
—
—
—
25
165
423
4318
77
490
331
3583
codeine and paracetamol
N02AJ06 [1123647]
5.1e-01
4.9e-01
—
—
6.2e-01
6.6e-01
3.8e-01
cases:15.35%
controls:9.85%
cases:6.58%
controls:4.13%
—
—
—
—
cases:1.54%
controls:0.84%
cases:7.14%
controls:3.81%
cases:17.40%
controls:12.64%
70
448
386
4099
30
188
426
4359
—
—
7
38
448
4507
32
171
416
4312
71
515
337
3558
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
1.5e-01
4.8e-02
—
—
—
3.7e-01
4.6e-01
cases:15.57%
controls:13.75%
cases:4.17%
controls:3.98%
—
—
—
—
—
—
cases:5.13%
controls:3.61%
cases:19.36%
controls:13.21%
71
625
385
3922
19
181
437
4366
—
—
—
23
162
425
4321
79
538
329
3535
tizanidine; oral
M03BX02 [21604116]
1.7e-01
6.4e-02
8.9e-01
—
8.0e-01
6.1e-01
4.4e-01
cases:14.69%
controls:12.71%
cases:4.61%
controls:4.33%
cases:1.54%
controls:0.64%
—
—
cases:1.32%
controls:0.59%
cases:7.59%
controls:4.28%
cases:19.85%
controls:13.70%
67
578
389
3969
21
197
435
4350
7
29
449
4518
—
6
27
449
4518
34
192
414
4291
81
558
327
3515
amoxicillin; oral, parenteral
J01CA04 [21602823]
3.1e-01
3.1e-02
—
—
—
-1.8e-01
4.4e-01
cases:22.59%
controls:17.68%
cases:5.48%
controls:5.32%
—
—
—
—
—
—
cases:5.13%
controls:6.11%
cases:27.21%
controls:19.42%
103
804
353
3743
25
242
431
4305
—
—
—
23
274
425
4209
111
791
297
3282
Acute atopic conjunctivitis
H10.1 [45605605]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
456
4542
—
—
—
—
—
—
Dislocation of acromioclavicular joint
S43.1 [45549575]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.18%
cases:0.00%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
0
8
456
4539
0
5
456
4542
—
—
—
—
—
Glucose [Moles/volume] in Serum or Plasma --1 hour post dose glucose
14756-1 [3015024]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
0
12
408
4061
Syphilis male
Y70 [2002001438]
—
—
1.0e+50
—
1.0e+50
—
—
—
—
—
—
cases:1.32%
controls:0.00%
—
—
cases:1.32%
controls:0.00%
—
—
—
—
—
—
6
0
450
4547
—
6
0
449
4545
—
—
Skin disease other
S99 [2002001063]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
456
4541
—
—
—
—
—
—
Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
43730-1 [3043849]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
456
4533
—
—
—
—
—
—
Fear of other disease NOS
A27 [2002000161]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
—
0
5
456
4542
—
—
—
—
—
Calculus of ureter
N20.1 [45582395]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
—
0
5
456
4542
—
—
—
—
—
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
-1.0e+50
—
—
—
—
—
5.7e-01
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:2.45%
controls:1.40%
0
24
456
4523
—
—
—
—
—
10
57
398
4016
gestodene and ethinylestradiol
G03AA10 [21602483]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
456
4542
—
—
—
—
—
—
Alcohol dependence currently independent
F10.20 [2000501677]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
0
6
448
4477
—
Clavicle X-ray examination
NB3AA [2001307250]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
8
408
4065
nystatin
D01AA01 [21601911]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
—
0
6
456
4541
—
—
—
—
—
Varicose veins of lower extremities without ulcer or inflammation
I83.9 [45552859]
-1.0e+50
-1.0e+50
—
—
—
—
7.0e-01
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.11%
—
—
—
—
—
—
—
—
cases:1.23%
controls:0.61%
0
25
456
4522
0
5
456
4542
—
—
—
—
5
25
403
4048
Microalbumin [Mass/volume] in Urine
14957-5 [3000034]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
—
0
5
448
4478
—
Unspecified fall
W19 [45756257]
7.0e-01
-1.0e+50
—
—
—
—
—
cases:1.10%
controls:0.55%
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
5
25
451
4522
0
8
456
4539
—
—
—
—
—
Public health laboratory ask at order entry panel
81959-9 [21494755]
-4.7e-02
3.6e-01
—
—
—
—
-9.1e-01
cases:1.97%
controls:2.07%
cases:1.10%
controls:0.77%
—
—
—
—
—
—
—
—
cases:1.23%
controls:3.00%
9
94
447
4453
5
35
451
4512
—
—
—
—
5
122
403
3951
Chronic ischaemic heart disease, unspecified
I25.9 [45552784]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
0
16
456
4531
0
6
456
4541
—
—
—
—
—
Polysomnography panel
90568-7 [1002224]
—
—
—
—
—
-1.0e+50
5.4e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:2.21%
controls:1.30%
—
—
—
—
—
0
12
448
4471
9
53
399
4020
Complement C3 [Mass/volume] in Serum or Plasma
4485-9 [3000620]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
17
408
4056
Other prophylactic chemotherapy
Z29.2 [45600313]
1.0e+50
1.0e+50
1.0e+50
—
—
1.0e+50
—
cases:2.63%
controls:0.00%
cases:3.51%
controls:0.00%
cases:1.54%
controls:0.00%
—
—
—
—
cases:5.13%
controls:0.00%
—
—
12
0
444
4547
16
0
440
4547
7
0
449
4547
—
—
23
0
425
4483
—
donepezil; oral
N06DA02 [21604795]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
8
408
4065
Ammonium ion [Moles/volume] in Plasma
1845-7 [3023183]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
456
4536
—
—
—
—
—
—
Other specified intervertebral disc degeneration
M51.3 [45591865]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
0
10
456
4537
—
—
—
0
7
448
4476
—
Epstein Barr virus Ab [Presence] in Serum
49178-7 [3048929]
6.3e-01
—
—
—
—
—
8.0e-01
cases:1.32%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.66%
6
32
450
4515
—
—
—
—
—
6
27
402
4046
Other mixed hyperlipidaemia
E78.29 [2000501518]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
0
7
456
4540
—
—
—
—
—
0
7
408
4066
Beta-2-Microglobulin [Mass/volume] in Serum or Plasma
1952-1 [3013201]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
456
4542
—
—
—
—
—
—
Care involving use of rehabilitation procedure, unspecified
Z50.9 [45595525]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
—
—
—
—
—
0
5
456
4542
—
—
—
—
—
magnesium hydroxide; oral
A02AA04 [21600052]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
456
4540
—
—
—
—
—
—
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
3.7e-01
-2.9e-03
—
—
—
7.6e-01
3.1e-01
cases:3.29%
controls:2.29%
cases:1.10%
controls:1.10%
—
—
—
—
—
—
cases:1.56%
controls:0.74%
cases:4.41%
controls:3.29%
15
104
441
4443
5
50
451
4497
—
—
—
7
33
441
4450
18
134
390
3939
Tension-type headache
G44.2 [45581495]
4.5e-01
—
—
—
—
—
2.5e-01
cases:1.10%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:1.15%
5
32
451
4515
—
—
—
—
—
6
47
402
4026
Health check-up performed during first study year due to special need in students of upper secondary schools or vocational schools
SPAT1365 [2001700466]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
—
—
—
—
—
—
0
7
408
4066
Unknown and unspecified causes of morbidity
R69 [45558480]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
0
5
408
4068
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
1.2e-01
—
—
—
—
—
-1.9e-02
cases:1.32%
controls:1.17%
—
—
—
—
—
—
—
—
—
—
cases:2.94%
controls:3.00%
6
53
450
4494
—
—
—
—
—
12
122
396
3951
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
X69 [45585661]
1.2e+00
2.0e+00
—
—
—
2.0e+00
1.6e+00
cases:1.54%
controls:0.48%
cases:1.10%
controls:0.15%
—
—
—
—
—
—
cases:1.12%
controls:0.16%
cases:1.47%
controls:0.29%
7
22
449
4525
5
7
451
4540
—
—
—
5
7
443
4476
6
12
402
4061
Eosinophil cationic protein (ECP) [Mass/volume] in Serum
25638-8 [3005791]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
—
—
—
—
—
—
0
7
408
4066
ferrous glycine sulfate; oral
B03AA01 [21601080]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.13%
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
0
11
456
4536
0
6
456
4541
—
—
—
0
8
448
4475
—
glucosamine; oral
M01AX05 [21604002]
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.11%
—
—
—
—
—
—
—
—
—
0
11
456
4536
0
5
456
4542
—
—
—
—
Cannabinoids [Presence] in Urine
3427-2 [3028300]
3.9e-01
—
—
—
—
—
4.1e-01
cases:2.63%
controls:1.80%
—
—
—
—
—
—
—
—
—
—
cases:2.94%
controls:1.96%
12
82
444
4465
—
—
—
—
—
12
80
396
3993
diclofenac
S01BC03 [21603641]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
456
4539
—
—
—
—
—
—
Monitoring of problem during pregnancy
SPAT1357 [2001700458]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
16
408
4057
Memory disturbance
P20 [2002000816]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
456
4537
—
—
—
—
—
—
Primary degenerative dementia of the Alzheimer's type, senile onset without additional symptoms
F00.10*G30.1 [2000501573]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
0
5
408
4068
Sinusitis acute/chronic
R75 [2002000943]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
0
11
456
4536
0
6
456
4541
—
—
—
—
0
13
408
4060
Chlamydial infection of pharynx
A56.4 [45571440]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.00%
—
—
—
—
—
—
8
0
400
4073
Asthma
J45 [45596282]
6.0e-02
1.4e+00
—
—
—
—
7.2e-01
cases:1.10%
controls:1.03%
cases:1.10%
controls:0.29%
—
—
—
—
—
—
—
—
cases:2.45%
controls:1.20%
5
47
451
4500
5
13
451
4534
—
—
—
—
10
49
398
4024
alfacalcidol; oral, parenteral
A11CC03 [21600818]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
cases:0.00%
controls:0.22%
0
6
456
4541
—
—
—
—
0
6
448
4477
0
9
408
4064
Tracheostomy
GBB00 [2001303560]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
0
5
408
4068
Nutritional therapy
R4190 [2001310243]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
456
4540
—
—
—
—
—
—
naproxen and esomeprazole; oral
M01AE52 [40254096]
—
—
—
—
—
—
1.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:1.30%
—
—
—
—
—
—
6
53
402
4020
Lesion of ulnar nerve
G56.2 [45595951]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
456
4537
—
—
—
—
—
—
Ulcerative colitis, unspecified
K51.9 [45605941]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.22%
—
—
—
—
—
—
6
9
402
4064
Medial epicondylitis
M77.0 [45557989]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.11%
—
—
—
—
—
—
—
0
5
448
4478
—
Vascular Surgery
77 [38004496]
3.0e-01
—
—
—
—
—
3.0e-01
cases:1.10%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:1.64%
5
37
451
4510
—
—
—
—
—
9
67
399
4006
UNS Panic Syndrome
F41.09 [2000501997]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.23%
controls:0.34%
—
—
—
—
—
—
5
14
403
4059
Sciatica
M54.3 [45586994]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
0
16
456
4531
—
—
—
—
0
7
448
4476
—
General medical examination
Z00.0 [45585791]
4.8e-01
—
—
—
—
—
1.9e-02
cases:2.85%
controls:1.78%
—
—
—
—
—
—
—
—
—
—
cases:2.45%
controls:2.41%
13
81
443
4466
—
—
—
—
—
10
98
398
3975
Parkinson disease
G20 [45538098]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.11%
cases:0.00%
controls:0.13%
—
—
—
—
—
—
cases:0.00%
controls:0.11%
cases:0.00%
controls:0.15%
0
5
456
4542
0
6
456
4541
—
—
—
0
5
448
4478
0
6
408
4067
Valproate [Moles/volume] in Serum or Plasma
14946-8 [3009466]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
0
11
448
4472
—
Base excess in Arterial blood by calculation
1925-7 [3003396]
—
—
—
—
—
—
-9.8e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.23%
controls:1.35%
—
—
—
—
—
—
5
55
403
4018
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
6.1e-01
—
—
—
—
—
8.4e-01
cases:1.54%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:2.70%
controls:1.18%
7
38
449
4509
—
—
—
—
—
11
48
397
4025
melatonin; oral
N05CH01 [21604659]
-4.6e-02
1.5e-01
—
—
-1.0e+50
1.3e-01
4.8e-01
cases:1.54%
controls:1.61%
cases:1.10%
controls:0.95%
—
—
—
—
cases:0.00%
controls:0.22%
cases:1.12%
controls:0.98%
cases:4.66%
controls:2.92%
7
73
449
4474
5
43
451
4504
—
—
0
10
455
4535
5
44
443
4439
19
119
389
3954
Extensive health check-up of children and adolescents
SPAT1316 [2001700417]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
0
27
456
4520
0
6
456
4541
—
—
—
—
0
6
408
4067
Maternal care due to uterine scar from previous surgery
O34.2 [45572805]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
cases:0.00%
controls:0.44%
—
—
—
—
—
0
6
448
4477
0
18
408
4055
glycerol
A06AX01 [21600597]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
0
8
456
4539
—
—
—
—
—
0
5
408
4068
Cervicobrachial syndrome
M53.1 [45567577]
-1.0e+50
-1.0e+50
—
—
—
—
5.8e-01
cases:0.00%
controls:0.66%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:1.96%
controls:1.10%
0
30
456
4517
0
11
456
4536
—
—
—
—
8
45
400
4028
Nonorganic insomnia
F51.0 [45552492]
1.5e-01
9.2e-01
—
—
—
8.6e-01
7.7e-01
cases:1.54%
controls:1.32%
cases:1.10%
controls:0.44%
—
—
—
—
—
—
cases:1.56%
controls:0.67%
cases:5.15%
controls:2.46%
7
60
449
4487
5
20
451
4527
—
—
—
7
30
441
4453
21
100
387
3973
Suture of gingiva
ECB00 [2001301968]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
0
10
456
4537
—
—
—
—
—
0
13
408
4060
Single live birth
Z37.0 [45571346]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
—
—
—
—
0
9
456
4538
—
—
—
—
—
progesterone; oral, parenteral, rectal, vaginal
G03DA04 [21602542]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:0.00%
controls:0.39%
—
—
—
—
—
0
11
448
4472
0
16
408
4057
Open wound of nose
S01.2 [45553788]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
456
4539
—
—
—
—
—
—
Other specified disorders of male genital organs
N50.8 [45582410]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
0
6
408
4067
Naevus, non-neoplastic
I78.1 [45533504]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
0
6
456
4541
—
—
—
—
—
0
5
408
4068
Angina pectoris, unspecified
I20.99 [2000502407]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
456
4531
—
—
—
—
—
—
ethinylestradiol; oral
G03CA01 [21602516]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.15%
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
0
17
456
4530
0
7
456
4540
—
0
6
455
4539
—
—
Puncture of pleura with ultrasound guidance
GA4YT [2001303531]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
—
—
—
—
—
—
0
7
408
4066
Flexible laryngoscopy
UDQ12 [2001301827]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
456
4535
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
262
87
58.90
307.65
13.2
1.8
9.96
—
titre
—
134
0
177
147
17.62
187.29
6.4
3.9
142.48
331.35
mg/l
1.32
154
71
113
40
35.69
173.00
2.8
2.2
32.32
35.25
%
0.59
113
40
106
32
41.21
170.07
2.9
3.2
29.53
43.64
%
2.92
16
18
274
617
8.17
130.61
4.8
1.8
—
—
—
0
0
271
702
6.89
108.99
6.1
1.7
—
—
—
0
0
183
469
5.45
70.30
4.9
1.5
—
—
—
0
0
154
427
4.68
52.23
2.2
3.0
31.90
42.31
u/l
0.48
146
364
64
97
7.37
41.31
1.2
1.1
—
—
—
0
0
227
966
3.37
39.87
4.1
3.4
—
0.00
—
0
8
290
1533
2.98
33.40
4.6
3.8
16.19
93.36
e6/l
1.96
157
1086
245
1185
2.99
33.16
8.9
2.0
—
—
—
0
0
59
105
6.20
32.51
1.2
1.1
—
—
—
0
0
252
1272
2.88
31.01
8.6
5.9
—
—
—
0
0
263
1442
2.64
26.36
11.1
6.4
—
—
—
0
0
73
204
3.99
23.41
1.3
1.4
222.19
227.69
miu/ml
0.04
27
113
156
700
2.75
22.83
2.3
2.9
0.79
0.81
e6/l
0.05
61
366
372
2536
2.59
21.90
13.5
9.8
3.76
4.14
e9/l
2.84
332
2226
342
2272
2.44
20.83
7.4
6.8
13.04
12.01
umol/l
0.43
330
2171
206
1104
2.42
20.43
2.7
3.0
—
0.00
estimate
—
0
7
339
2264
2.39
20.08
12.2
6.6
0.58
0.58
e9/l
0.05
309
1966
339
2267
2.39
19.98
12.1
6.6
0.04
0.04
e9/l
0.75
309
1970
143
655
2.62
19.76
2.3
3.0
2.81
1.37
e6/l
0.53
48
318
344
2324
2.38
19.66
12.1
6.8
2.08
2.00
e9/l
0.50
316
2082
346
2345
2.38
19.61
12.1
7.0
0.19
0.20
e9/l
0.49
317
2079
295
1875
2.30
19.36
4.0
3.1
6.19
6.14
ph
0.23
108
1124
318
2090
2.32
19.21
12.7
6.8
8.88
8.79
%
0.32
305
1995
316
2079
2.30
18.93
12.7
6.6
2.80
2.90
%
0.41
303
1978
315
2073
2.29
18.81
12.8
6.8
0.74
0.69
%
1.20
302
1968
320
2122
2.29
18.73
12.4
6.5
53.09
56.93
%
7.44
310
2049
323
2155
2.29
18.56
12.6
6.6
32.42
28.16
%
8.56
311
2070
208
1158
2.32
18.53
2.8
3.1
0.22
0.33
e6/l
0.80
129
843
279
1761
2.24
18.26
5.2
5.4
37.84
36.69
g/l
2.65
263
1681
175
924
2.34
17.46
2.1
1.7
—
—
—
0
0
224
1337
2.17
16.36
3.0
3.2
16.54
101.90
e6/l
1.08
146
1022
50
143
3.76
15.39
1.6
1.3
—
—
—
0
0
296
2009
2.08
14.99
15.4
10.7
0.00
0.00
e9/l
0.46
251
1650
326
2306
2.08
14.60
4.0
3.3
0.00
0.00
estimate
-0.00
42
490
329
2336
2.09
14.57
4.1
3.4
0.00
0.02
estimate
1.06
38
442
328
2333
2.07
14.37
4.0
3.3
0.00
3.31
estimate
0.50
42
491
416
3276
2.28
13.49
9.6
8.3
76.20
77.53
u/l
0.30
408
3142
251
1667
1.97
12.84
10.4
3.3
36.55
34.95
u/l
0.10
241
1586
102
501
2.28
11.55
1.8
1.7
—
—
—
0
0
37
113
3.45
10.33
2.1
1.1
—
—
—
0
0
334
2607
1.77
8.82
4.2
3.9
382.00
137.18
e6/l
—
5
39
20
47
4.38
8.00
1.9
1.7
—
—
—
0
0
324
2548
1.71
7.93
6.1
5.5
6.39
6.70
mmol/l
2.18
318
2409
495
4474
2.75
7.63
15.4
14.0
24.51
23.45
mg/l
0.32
428
3622
255
1913
1.65
7.23
2.2
1.9
1.41
1.49
mmol/l
0.87
241
1680
105
639
1.80
6.32
2.4
2.1
—
—
—
0
0
28
99
2.93
6.20
1.7
1.4
—
—
—
0
0
27
94
2.97
6.14
2.4
3.4
2.00
2.77
index
—
8
59
36
148
2.54
6.00
2.1
3.4
—
—
—
0
0
38
162
2.45
5.88
2.3
3.1
1.12
1.32
mg/l
2.20
32
151
17
45
3.87
5.85
2.1
1.5
—
—
—
0
0
200
1507
1.53
5.05
3.2
3.6
8.81
8.76
mmol/l
0.04
177
1317
49
250
2.06
4.97
3.0
3.5
23.77
24.37
mmol/l
0.55
49
250
56
300
1.97
4.97
2.0
1.8
0.26
0.35
mg/l
0.72
32
153
90
563
1.72
4.88
1.6
1.5
—
—
—
0
0
49
253
2.03
4.82
1.2
1.2
—
—
—
0
0
164
2153
0.65
4.77
3.0
2.9
—
—
—
0
0
61
349
1.85
4.46
1.8
2.4
—
—
—
0
0
112
760
1.60
4.42
2.5
2.5
15.26
14.34
nmol/l
0.57
106
717
130
914
1.56
4.41
2.6
2.5
4.39
5.69
e6/l
0.56
118
837
182
1376
1.49
4.40
2.3
2.3
—
—
—
0
0
64
378
1.79
4.22
1.8
2.3
—
—
—
0
0
64
379
1.78
4.19
1.8
2.3
—
—
—
0
0
63
373
1.78
4.13
1.8
2.3
—
—
—
0
0
59
343
1.81
4.10
2.0
2.0
40.41
36.61
nmol/l
0.52
59
333
7
7
10.11
4.02
3.0
1.4
—
—
—
0
0
152
1138
1.47
3.77
4.6
4.5
—
—
—
0
0
142
1054
1.48
3.67
1.7
1.6
19.84
19.64
nmol/l
0.06
127
914
25
111
2.31
3.60
1.8
1.4
23.65
21.96
e6/l
0.04
17
81
61
373
1.72
3.59
1.8
2.1
—
—
—
0
0
458
4230
1.63
3.56
6.0
4.5
5.91
5.92
mmol/l
0.01
437
3977
503
4781
2.14
3.43
23.8
17.1
78.12
79.27
umol/l
0.56
503
4743
25
114
2.25
3.40
1.8
1.4
474.65
855.40
e6/l
0.21
17
85
9
18
5.07
3.38
4.6
2.1
35.89
33.61
%
—
9
18
214
1746
1.38
3.19
6.2
7.3
1.20
1.21
mmol/l
0.64
200
1645
193
1550
1.39
3.16
2.3
2.0
—
—
—
0
0
14
50
2.85
3.11
1.4
1.8
—
—
—
0
0
20
87
2.35
3.04
2.1
2.6
1.56
2.11
mmol/l
0.73
15
57
17
69
2.51
2.99
1.0
1.2
—
—
—
0
0
38
214
1.84
2.97
1.5
1.6
7.84
6.18
u/l
0.39
30
181
29
149
2.00
2.96
1.2
1.1
—
—
—
0
0
109
801
1.45
2.92
2.5
2.6
572.22
557.01
mosm/kgh2o
0.24
95
707
47
286
1.71
2.84
1.9
2.0
230.15
220.59
pmol/l
0.25
47
273
97
701
1.47
2.83
2.9
2.9
2.43
2.43
mmol/l
0.32
84
628
12
39
3.12
2.78
1.0
1.1
—
—
—
0
0
5
6
8.40
2.75
1.4
1.3
—
—
—
0
0
11
34
3.28
2.74
1.0
1.1
—
—
—
0
0
163
1299
1.37
2.73
3.2
3.5
2.36
2.35
mmol/l
0.35
148
1201
472
4447
1.59
2.71
16.5
16.0
3.94
3.98
mmol/l
2.90
463
4366
88
630
1.48
2.69
1.4
1.4
446.67
403.31
titre
0.16
18
121
202
1674
1.34
2.60
2.2
1.9
98.60
95.61
pmol/l
0.37
122
908
32
179
1.84
2.58
1.3
1.3
—
—
—
0
0
470
4437
1.55
2.52
16.4
15.9
139.39
139.68
mmol/l
2.05
465
4367
448
4193
1.46
2.46
6.9
5.6
37.83
38.76
mmol/mol
0.45
437
4017
29
160
1.86
2.44
4.0
10.4
—
—
—
0
0
146
1163
1.35
2.42
3.4
4.2
7.40
7.40
ph
0.09
91
824
9
27
3.37
2.40
1.3
1.6
—
3280.00
—
0
5
72
509
1.48
2.35
1.3
1.2
—
—
—
0
0
62
426
1.52
2.32
2.3
2.8
1.63
1.79
%
0.89
57
389
14
59
2.41
2.31
1.4
1.4
196.17
165.48
pmol/l
0.73
14
59
19
93
2.08
2.24
2.4
2.6
—
—
—
0
0
5
9
5.60
2.22
3.6
1.6
—
—
—
0
0
17
80
2.16
2.21
1.1
1.0
2.20
1.79
eliau/ml
—
7
36
213
1814
1.29
2.16
2.5
2.5
75.57
73.38
nmol/l
0.50
194
1677
80
587
1.43
2.16
2.0
2.5
25.63
24.89
%
0.14
75
558
24
131
1.87
2.11
1.1
1.1
—
—
—
0
0
24
132
1.86
2.07
1.1
1.1
—
—
—
0
0
125
995
1.34
2.06
1.5
1.4
2.55
2.44
g/l
0.32
72
684
123
980
1.33
2.01
2.3
2.0
2.79
2.73
mg/l
0.10
107
857
38
242
1.61
1.99
1.2
2.3
—
—
—
0
0
56
390
1.49
1.98
2.0
2.6
0.22
0.22
g/l
0.14
51
365
139
1131
1.31
1.96
2.5
2.6
351.00
358.14
umol/l
0.40
130
1030
8
28
2.88
1.87
1.0
1.3
130.88
156.78
nmol/l
—
8
28
111
1374
0.76
1.86
3.0
2.7
0.00
0.00
estimate
0.50
34
396
54
385
1.45
1.72
8.3
10.9
—
—
—
0
0
512
4991
1.91
1.71
26.7
20.7
252.42
247.74
e9/l
0.89
504
4923
45
311
1.49
1.68
1.5
1.4
—
—
—
0
0
83
642
1.35
1.66
2.0
2.5
2.29
2.31
g/l
0.10
78
598
7
25
2.82
1.65
1.6
3.4
909.57
736.84
u/ml
—
7
25
38
255
1.53
1.63
1.6
1.2
—
—
—
0
0
126
1039
1.28
1.59
3.3
3.3
1.02
1.02
kg/l
1.38
65
676
10
43
2.35
1.59
1.1
1.2
39.64
51.78
mg/l
—
10
31
512
4998
1.86
1.59
26.7
20.7
6.81
6.68
e9/l
0.68
499
4922
512
4998
1.86
1.59
26.6
20.6
4.58
4.67
e12/l
3.89
499
4922
113
925
1.28
1.51
2.9
2.7
—
—
—
0
0
0
45
0.00
1.50
0.0
2.5
—
105.89
—
0
45
0
45
0.00
1.50
0.0
2.5
—
4.03
—
0
45
0
45
0.00
1.50
0.0
2.5
—
1.18
—
0
45
353
3282
1.23
1.43
3.7
3.8
14.70
14.64
pmol/l
0.16
330
3045
99
805
1.28
1.40
3.1
3.5
1314.97
691.69
ng/l
0.22
72
574
224
1996
1.21
1.38
2.8
2.7
—
—
estimate
—
0
0
9
42
2.16
1.34
1.1
1.1
271.67
253.18
mg/l
—
9
34
81
646
1.30
1.33
2.8
2.8
92.68
125.56
ug/g
0.95
64
538
0
40
0.00
1.33
0.0
1.5
—
76.60
—
0
40
220
1963
1.21
1.33
6.1
7.9
1.20
1.21
mmol/l
0.15
192
1734
76
603
1.30
1.30
7.7
8.3
104.79
104.05
mmol/l
0.85
76
603
43
313
1.41
1.27
2.0
2.9
65.20
71.14
e9/l
0.63
29
217
54
410
1.35
1.25
3.5
3.6
0.67
1.82
mmol/l
1.05
49
352
10
187
0.53
1.21
6.2
7.6
2.28
1.59
%
—
10
172
55
422
1.34
1.19
3.6
3.7
7.37
7.38
ph
0.42
25
242
17
102
1.69
1.17
1.1
1.0
2.70
8.51
u/ml
—
8
62
0
33
0.00
1.16
0.0
2.9
—
48.82
—
0
33
0
33
0.00
1.16
0.0
5.8
—
7.97
—
0
33
0
35
0.00
1.15
0.0
1.7
—
6.17
—
0
26
226
2043
1.19
1.14
2.9
2.9
132.57
139.17
ug/l
0.18
215
1948
7
32
2.20
1.08
1.6
1.5
—
—
—
0
0
63
501
1.29
1.08
8.0
10.7
7.41
7.42
ph
0.21
37
274
45
585
0.75
1.08
1.5
1.4
—
—
—
0
0
7
33
2.14
1.06
1.0
1.3
—
—
—
0
0
16
98
1.65
1.04
1.1
1.0
6.13
0.64
u/ml
—
10
39
7
34
2.07
1.03
1.9
1.6
—
—
—
0
0
5
23
2.18
0.98
1.2
1.1
656.08
157.89
iu/ml
—
5
23
10
54
1.87
0.97
1.1
1.9
8.25
11.44
%
—
10
54
0
31
0.00
0.96
0.0
1.3
—
—
—
0
0
19
125
1.54
0.95
1.0
1.2
315.85
259.03
u/ml
0.41
13
77
22
151
1.48
0.92
1.7
2.1
0.39
1.70
ug/l
1.29
17
133
61
497
1.26
0.89
8.2
10.7
0.33
0.91
mmol/l
0.63
53
423
13
79
1.66
0.88
1.2
1.0
0.16
0.38
u/ml
—
6
25
16
103
1.57
0.88
2.4
3.3
55.13
57.61
%
0.39
16
103
22
153
1.46
0.87
1.2
1.3
—
—
—
0
0
30
222
1.37
0.85
1.3
1.3
—
—
—
0
0
6
31
1.95
0.84
1.0
1.0
—
—
—
0
0
8
46
1.75
0.83
2.8
1.3
6.35
7.00
g/l
—
8
30
8
46
1.75
0.83
2.8
1.3
0.57
0.40
g/l
—
8
29
23
164
1.42
0.81
1.6
2.2
124.75
570.14
ug/l
1.00
23
158
8
47
1.71
0.81
2.8
1.3
—
—
—
0
0
33
251
1.34
0.80
4.2
6.7
—
—
—
0
0
0
24
0.00
0.79
0.0
1.5
—
—
—
0
0
6
33
1.83
0.79
2.7
1.8
—
—
—
0
0
0
26
0.00
0.78
0.0
1.3
—
35.57
—
0
19
46
369
1.27
0.77
1.2
1.2
—
—
—
0
0
6
34
1.77
0.76
1.5
1.5
16100.00
29490.41
e6/l
—
6
17
0
28
0.00
0.76
0.0
1.0
—
—
—
0
0
10
59
1.71
0.76
1.2
1.1
—
—
—
0
0
42
335
1.28
0.74
1.1
1.1
—
—
—
0
0
7
38
1.85
0.73
1.1
1.3
—
—
—
0
0
7
38
1.85
0.73
1.4
1.4
3324.57
2411.52
e6/l
—
7
23
5
25
2.01
0.73
2.6
3.5
89.40
126.32
nmol/l
—
5
25
63
531
1.21
0.70
2.2
2.8
11.00
8.74
umol/l
0.27
53
473
469
4582
1.21
0.69
6.9
5.1
2.80
2.80
mmol/l
0.01
451
4354
7
42
1.68
0.68
1.6
2.5
27.43
33.07
pg
—
7
42
5
27
1.86
0.68
1.0
1.1
—
—
—
0
0
7
43
1.64
0.67
1.3
1.1
—
—
—
0
0
143
1297
1.14
0.66
3.1
3.7
71.57
61.74
mg/l
0.13
88
890
10
62
1.62
0.65
4.6
3.5
1.75
1.06
%
—
10
57
123
1105
1.15
0.65
1.4
1.3
1.23
1.30
u/ml
0.06
33
327
66
564
1.19
0.64
2.0
3.7
4.20
6.13
e9/l
1.02
57
515
414
4012
1.15
0.64
4.8
4.6
1.76
1.85
mu/l
0.99
396
3757
84
735
1.17
0.63
1.9
1.5
—
—
—
0
0
24
182
1.33
0.62
2.6
2.6
262.90
4311.79
u/l
—
6
71
153
1400
1.13
0.61
2.9
2.9
61.01
64.21
u/l
0.18
141
1318
145
1324
1.13
0.60
3.7
4.3
13.46
10.12
mg/mmol
0.21
90
886
113
1017
1.14
0.59
1.8
1.7
1.13
1.16
mg/l
0.05
86
760
6
36
1.67
0.57
2.0
2.4
—
—
—
0
0
6
36
1.67
0.57
1.8
1.2
111.00
108.11
pmol/l
—
6
36
6
36
1.67
0.57
1.0
2.6
—
—
—
0
0
464
4544
1.18
0.56
6.3
4.7
4.61
4.65
mmol/l
0.40
446
4329
31
383
0.80
0.56
5.6
5.4
0.00
0.20
%
1.18
13
91
31
382
0.80
0.55
5.4
4.7
0.50
0.46
%
0.07
14
113
6
39
1.54
0.53
1.8
1.3
4.38
6.32
mmol/l
—
6
34
6
40
1.51
0.51
1.3
1.1
—
—
—
0
0
9
64
1.41
0.51
2.8
1.6
—
—
—
0
0
9
64
1.41
0.51
2.8
1.6
—
—
—
0
0
9
64
1.41
0.51
2.8
1.6
—
—
—
0
0
9
64
1.41
0.51
2.8
1.6
—
—
—
0
0
12
168
0.71
0.51
4.3
8.1
3.24
0.87
%
0.49
12
152
14
190
0.73
0.50
3.8
3.3
25.14
24.91
mmol/l
0.13
14
181
13
93
1.41
0.48
1.2
1.0
5.39
2.67
u/ml
—
7
49
5
81
0.61
0.46
1.0
1.1
—
—
—
0
0
16
121
1.33
0.44
1.3
1.1
3.04
2.39
u/ml
—
9
68
10
69
1.46
0.44
2.0
1.3
—
—
—
0
0
13
95
1.38
0.44
1.3
1.2
—
—
—
0
0
29
240
1.22
0.42
2.6
2.5
0.66
0.66
%
0.02
29
240
5
32
1.57
0.42
1.0
1.3
—
—
—
0
0
361
3506
1.09
0.41
3.3
3.4
46.22
48.23
u/l
0.21
343
3371
0
15
0.00
0.41
0.0
1.8
—
2.40
—
0
15
0
15
0.00
0.41
0.0
1.2
—
67.20
—
0
15
149
1393
1.10
0.41
1.4
1.5
—
—
—
0
0
440
4315
1.12
0.41
5.2
4.0
1.38
1.36
mmol/l
0.29
412
4079
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
23
186
1.25
0.41
1.5
1.9
1.83
5.08
iu/ml
—
6
40
11
79
1.40
0.41
1.1
1.5
—
—
—
0
0
79
716
1.12
0.39
1.3
1.3
10.07
7.14
u/ml
0.14
43
300
30
355
0.84
0.39
1.8
2.0
0.00
0.00
estimate
—
6
97
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
11
80
1.38
0.38
1.5
1.6
0.25
0.34
nmol/l
—
5
59
83
756
1.12
0.38
1.5
1.7
434.82
28097107.12
pmol/l
0.77
72
662
5
37
1.35
0.37
1.4
3.4
1389.80
1621.38
mg
—
5
37
11
81
1.37
0.36
3.2
3.6
3.67
4.11
e9/l
0.38
11
81
127
1186
1.09
0.36
2.6
2.6
0.59
0.70
ug/l
1.10
80
617
5
78
0.64
0.36
1.2
1.1
—
—
—
0
0
34
292
1.18
0.35
1.2
1.3
34.19
110.50
u/ml
—
9
118
6
43
1.40
0.35
1.0
1.0
—
—
—
0
0
6
46
1.31
0.33
1.8
1.2
—
—
—
0
0
6
89
0.67
0.33
7.2
12.3
12.67
11.74
mmol/l
—
6
77
6
89
0.67
0.33
7.2
12.3
104.33
105.00
mmol/l
—
6
77
35
401
0.86
0.32
5.2
4.8
1.14
0.87
%
0.25
18
126
15
119
1.27
0.32
1.1
1.4
—
—
—
0
0
12
151
0.79
0.28
4.5
2.3
25.27
24.92
mmol/l
0.12
12
151
24
279
0.85
0.27
1.3
1.1
0.71
0.67
ratio
—
6
29
474
4692
1.10
0.24
13.3
12.1
—
—
—
0
0
18
212
0.84
0.24
1.8
2.0
0.00
3.16
estimate
—
5
79
6
84
0.71
0.24
1.0
1.1
—
—
—
0
0
131
1249
1.06
0.23
3.8
3.4
0.00
0.01
estimate
0.69
37
455
12
97
1.24
0.23
2.4
2.2
143.29
134.93
g/l
—
7
72
34
378
0.89
0.22
5.4
4.9
0.00
0.13
%
2.61
17
102
158
1644
0.94
0.22
3.4
3.4
21.07
33.69
ng/l
1.89
93
1053
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
6.1
—
7.38
—
0
10
0
13
0.00
0.21
0.0
1.2
—
1.13
—
0
7
30
331
0.90
0.18
1.9
2.2
7.00
9.18
ug/l
0.58
25
301
11
91
1.21
0.17
1.5
1.2
5.00
4.34
u/ml
—
6
47
5
67
0.74
0.17
2.2
2.6
—
—
—
0
0
8
68
1.18
0.16
2.4
1.5
—
—
—
0
0
457
4533
1.06
0.15
6.3
4.6
1.32
1.37
mmol/l
1.73
436
4299
9
80
1.13
0.15
1.1
1.2
16.69
16.26
u/l
—
9
72
19
169
1.13
0.14
2.0
2.2
—
—
—
0
0
59
558
1.06
0.14
1.2
1.3
—
—
—
0
0
18
160
1.13
0.14
1.3
1.7
—
—
—
0
0
16
141
1.14
0.14
1.2
2.4
10.49
11.85
mg/l
0.49
16
134
34
316
1.08
0.13
3.8
4.6
7.38
7.34
ph
1.81
22
244
36
336
1.08
0.12
2.9
2.4
0.67
0.18
e6/l
0.94
30
323
12
104
1.16
0.12
3.0
2.0
8.78
8.37
kpa
0.54
12
104
17
152
1.12
0.12
1.6
1.9
—
—
—
0
0
311
3073
1.03
0.10
3.7
3.6
—
0.17
—
0
6
82
792
1.04
0.10
1.5
1.3
37.53
25.90
iu/ml
0.41
22
223
5
45
1.11
0.10
1.8
2.4
—
—
—
0
0
13
116
1.12
0.09
1.8
1.9
—
—
—
0
0
17
186
0.91
0.09
3.1
3.5
—
—
—
0
0
197
1938
1.03
0.09
4.6
4.1
2.82
1.76
ug/l
0.66
184
1784
6
54
1.11
0.09
2.3
3.2
1.32
2.83
nmol/l
—
6
54
6
70
0.86
0.07
3.2
2.3
—
—
—
0
0
54
523
1.04
0.06
1.4
1.4
—
—
—
0
0
27
284
0.95
0.06
3.2
3.2
5.07
5.15
kpa
0.21
27
277
19
202
0.94
0.05
1.1
1.1
—
—
—
0
0
112
1139
0.98
0.05
5.3
5.1
—
—
—
0
0
51
525
0.97
0.05
1.9
1.7
3.42
3.52
mmol/l
0.26
38
370
27
282
0.96
0.04
2.6
3.1
120.67
133.42
g/l
1.37
27
272
34
328
1.04
0.04
1.9
2.1
5.80
6.12
ph
1.51
20
208
12
111
1.08
0.04
1.1
2.6
0.99
1.72
ratio
—
7
60
56
550
1.02
0.02
1.6
1.6
1139.91
1204.12
nmol/l
0.23
43
432
25
258
0.97
0.02
11.4
13.2
16.32
16.26
%
0.03
25
247
25
243
1.03
0.01
1.2
1.6
—
—
—
0
0
35
357
0.98
0.01
3.7
3.4
—
—
—
0
0
44
433
1.02
0.01
10.1
11.6
124.80
125.14
g/l
0.04
44
422
13
136
0.95
0.00
2.8
2.8
—
—
—
0
0
19
184
1.03
0.00
1.4
1.2
0.52
1.92
u/ml
—
5
15
27
272
0.99
0.00
3.2
3.3
7.40
7.42
ph
0.55
20
228
187
1868
1.00
0.00
11.9
11.3
1.22
1.18
inr
0.42
144
1547
0
7
0.00
0.00
0.0
1.1
—
87.34
—
0
7
0
7
0.00
0.00
0.0
1.3
—
2.13
—
0
7
9
96
0.94
-0.00
1.8
1.6
—
—
—
0
0
182
1820
1.00
-0.00
3.3
3.1
0.00
0.01
estimate
0.74
34
412
0
9
0.00
-0.00
0.0
1.2
—
0.04
—
0
9
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.8
—
206.60
—
0
5
0
5
0.00
-0.00
0.0
5.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
5
50
1.00
-0.00
1.0
1.3
26.64
32.47
ng/l
—
5
50
5
59
0.85
-0.00
1.2
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.8
—
1.20
—
0
9
0
8
0.00
-0.00
0.0
2.8
—
—
—
0
0
9
95
0.95
-0.00
1.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
402.00
—
0
5
0
5
0.00
-0.00
0.0
3.4
—
1.04
—
0
5
9
96
0.94
-0.00
1.8
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
60.00
—
0
5
5
50
1.00
-0.00
1.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.2
—
0.20
—
0
5
7
78
0.90
-0.00
1.6
2.9
6.00
7.98
pmol/l
—
7
78
5
57
0.88
-0.00
1.2
1.2
1.33
1.57
nmol/l
—
5
52
8
87
0.92
-0.00
1.6
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
70.00
—
0
8
5
51
0.98
-0.00
3.0
2.4
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: AB1_EARLY_SYPHILIS_WIDE – Early syphilis, including avohilmo

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).